85 results on '"Payot L"'
Search Results
2. Ticagrelor versus clopidogrel for complex percutaneous coronary intervention in chronic coronary syndrome: a post-hoc analysis of the ALPHEUS study
- Author
-
Lattuca, B, primary, Mazeau, C, additional, Guedeney, P, additional, Kala, P, additional, Nejjari, M, additional, Morel, O, additional, Leclercq, F, additional, Payot, L, additional, Beygui, F, additional, Range, G, additional, Motovska, Z, additional, Vicaut, E, additional, Collet, J P, additional, Montalescot, G, additional, and Silvain, J, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Recherche de l’ischémie myocardique silencieuse chez le diabétique
- Author
-
Payot, L.
- Published
- 2015
- Full Text
- View/download PDF
4. ÉVALUATION DE L'ASTREINTE THERMIQUE À L'AIDE DE LA FRÉQUENCE CARDIAQUE
- Author
-
Meyer, J.-P., Martinet, C., Payot, L., Didry, G., and Horwat, F.
- Published
- 2001
5. Dissection coronaire spontanée dans le SCA ST+ chez un homme jeune : échec de fibrinolyse
- Author
-
Ndao, S.C.T., Ben Amara, W., Zabalawi, A., Khounlaboud, M., Payot, L., and Delaunay, R.
- Published
- 2021
- Full Text
- View/download PDF
6. Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study
- Author
-
Cayla, G, Silvain, J, Barthelemy, O, Connor, S ʼO, Payot, L, Bellemain-Appaix, A, Beygui, F, Aout, M, Collet, J-P, Vicaut, E, and Montalescot, G
- Published
- 2011
- Full Text
- View/download PDF
7. THE CONTRIBUTION OF THE FRACTIONNAL FLOW RESERVE IN THE CONFIRMATION OF MYOCARDIAL ISCHEMIA REVEALED BY VENTRICULAR RYTHM DISORDERS: REPORT ON TWO CASES AND A LITERARY REVIEW
- Author
-
R. Delaunay, Momar Dioum, B. Moquet, Maboury Diao, Bodi S, Joseph Salvador Mingou, Ndao Sct, A. Zabalawi, Taldir G, and Payot L
- Subjects
medicine.medical_specialty ,Myocardial ischemia ,Flow (mathematics) ,business.industry ,Internal medicine ,medicine ,Cardiology ,business - Published
- 2017
- Full Text
- View/download PDF
8. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients
- Author
-
Legkonogov, O., Ramacciotti, E., Mikhailova, E., Koryk, V., Adzerikho, I., Schoenerr, H., Mathies, R., Konig, J., Huber, K., Rubinfeld, A., Finfer, S., Manenti, E., Bott, M., Blessing, E., Beyer-Westendorf, J., Coughlin, P., Baker, R., Poy, C., Dengler, T., Parody, M., Oliva, M., Macin, S., Jure, H., Ferrari, A. E., Dziewas, R., Genth-Zotz, S., Hamann, F., Horacek, T., Klimpe, S., Mitkovskaya, N., Kroning, R., Lapp, H., Lawall, H., Licka, M., Rizos, T., Tiefenbacher, C., Weimar, C., Alkonyi, B., Falukozy, J., Futo, L., Katona, A., Berrouschot, J., Kirschner, R., Amann, B., Paposhvili, K., Pagava, Z., Kristof, P., Lakatos, F., Laszlo, Z., Freire, A., Lupkovics, G., Megreladze, I., Kobulia, B., Khintibidze, I., Khabeishvili, G., Datikashvili-David, I., Simoneau, G., Merkely, B., Andras, C. Nagy, Nemeth, L., Papp, A., Soltesz, P., Fiss, E., Schmidt, J., Roy, P-M., Quere, I., Proust, A., Pottier, P., Pernod, G., Payot, L., Bizzacchi, J. Annichino, Lienart, F., Paleiron, N., Montaclair, K., Mismetti, P., Messas, E., Lacroix, P., Grange, C., Falvo, N., El Kouri, D., Decoulx, E., Debourdeau, P., De Geeter, G., Brisot, D., Belhassane, A., Aquilanti, S., Agraou, B., Vikman, S., Tatlisumak, T., Saarinen, J., Kaaja, R., Honkaniemi, J., Airaksinen, J., Uuetoa, T., Lember, M., Urhammer, S., Tuxen, C., Storgaard, M., Lassen, M., Christensen, H., Vyhnanek, M., Vejvoda, J., Spacek, R., Reiterer, P., Podpera, I., Mikulova, J., Lang, P., Jajtner, P., Hubac, J., Horny, I., Holaj, R., Herold, M., Havelka, J., Francek, L., Dusek, J., Dunaj, M., Cizek, V., Chochola, J., Chlumsky, J., Cermak, O., Skerk, V., Vagic, J. Sikic, Marusic, S., Knezevic, A., Kalinic-Grgorinic, H., Jakopovic, M., Francetic, I., Ciglenecki, N., Car, S., Butkovic-Soldo, S., Cardenas, S. Potthoff, Lazcano, M. Opazo, Alarcon, M. Arias, Verreault, S., Provencher, S., Pearce, M., Le Gal, G., Douketis, J., Dhar, A., Tokmakova, M., Todorov, G., Syulemzova, S., Raymuno, S., Rocha, A., Dimov, B., Grigorov, M., Kalpachki, R., Kamenova, Z., Bello, F., Harrington, Robert A., Bandman, Olga, Kostadinova, M., Milanova, M., Dive, A., Pencheva, G., Sudar, Z., Szabo, G., Szegedi, N., Timar, G., Valco, J., Delforge, M., Vertes, A., Efrati, S., Elias, M., Gafter, A., Nazliel, BİJEN, Hayek, T., Hussein, O., Lishner, M., Lugassy, G., Cerveri, I., D'Angelo, A., De Pellegrin, A., Imberti, D., Landolfi, R., Runev, N., Lembo, G., Lodigiani, C., Moia, M., Molteni, M., Mumoli, N., Novo, S., Orlandini, F., Stoeva, N., Parisi, R., Pizzini, A., Pomero, F., Salvi, A., Schenone, A., Gold, Alex, Visona, A., Martinova, V., Pontaga, N., Rozitis, V., Stukena, I., Alekniene, B., Basijokiene, V., Butkiene, Z., Griskeviciene, V., Naudziunas, A., Stoyanov, M., Norvaisiene, R., Norviliene, R., Petrauskiene, R., Poskiene, R., Susinskiene, D., Valavicius, A., Castillo Leon, R., Pimanov, S., Polonetsy, L., Pereyra, R. Cotrina, Karlo, L. Farjardo, Horna, M., Soroka, N., Salas, M., Yanez, L. Toche, Fryze, W., Gaciong, Z., Gniot, J., Gorecka, D., Gruenpeter, P., Grzelakowski, P., Jastrzebski, D., Kucharski, L., Mirek-Bryniarska, E., Pulkowski, G., Sobkowicz, B., Sulik, P., Walasek, L., Blockmans, D., Waldemar, K., Wrzesinski, K., Balogh, Z. E., Bojinca, M., Marin, I., Musetescu, R., Podoleanu, C., Popescu, M., Stamate, S., Stanciulescu, G., Vida-Simiti, L., Abashev, A., Andreev, D., Apartsin, K., Arkhipov, M., Averkov, O., Barbarash, O., Belskaya, G., Bogdanov, E., Boldueva, S., Chefranova, Z., Dovgalevskiy, Y., Ershova, O., Goloshchekin, B., Khachatryan, N., Klein, G., Kobalava, Z., Kosmacheva, E., Kostenko, V., Malygin, A., Martynenko, T., Martynenko, V., Maslova, N., Mordovin, V., Nikolaev, K., Nilk, R., Popov, D., Privalova, E., Reshetko, O., Shapovalova, Y., Shpagina, L., Shvarts, Y., Simanenkov, V., Solovyov, O., Vishneva, E., Vishnevskiy, A., Apostolovic, S., Celic, V., Ilic, S., Kovacevic-Kuzmanovic, A., Miloradovic, V., Bodikova, S., Cervenakova, A., Dvorak, M., Herman, O., Hrubon, A., Kokles, M., Krastev, G., Payer, J., Prokop, D., Spisakova, M., Adler, D., Basson, M., Breedt, J., Engelbrecht, J., Mitha, I., Van Dyk, C., Alvarez Sala, L. A., Barbagelata Lopez, C., Bisbe, J., Castro Guardiola, A., Cepeda, J. M., Cereto, F., Diaz Santos, E., Ferrer, R., Gomez Cerezo, J., Hernandez, Adrian F., Gonzales-Porras, J. R., Grandes, J., Cohen, Alexander T., Gibson, C. Michael, Chi, Gerald, Halaby, Rim, Korjian, Serge, Daaboul, Yazan, Jain, Purva, Arbetter, Douglas, Goldhaber, Samuel Z., Hull, Russel, Jimenez, D., Mellibovsky, L., Richart, C., Riera, A., Trujillo, J., Vargas Nunez, J. A., Villalta, J., Akgul, O., Guneri, S., Kilichesmez, K., Kirma, C., Kutluk, H., Okumus, G., Tigen, K., Topcuoglu, M., Tuncay, E., Abrahamovych, O., Batushkin, V., Brozhyk, J., Burmak, I., Godlevska, O., Goloborodko, A., Goloborodko, B., Goncharova, Y., Gryb, V., Karpenko, O., Kopytsya, M., Zakai, N., Yousef, K., Wichman, T., Whitman, B., Welker, J., Welch, M., Warner, A., Updegrove, J., Tuck, M., Stoltz, S., Sokol, S., Sharma, S., Shammas, N., Saba, F., Rodriguez, W., Rees, C., Rastogi, P., Rajan, R., Quintana, O., Pullman, J., Pratt, R., Pineda, L., Pearl, R., Parthiban, K., Overcash, J., Ortel, T., Ohaju, V., Nadar, V., Mittal, M., Milling, T., McLaren, G., Margolis, B., Mahal, S., Macchiavelli, A., Lopez, J., Lerner, R., Kung, M., Kouras, F., Kazimir, M., Kao, C-K., Kabler, H., Ioachimescu, O., Hazelrigg, M., Hamad, A., Haidar, A., Hahn, B., Goytia-Leos, D., Gaggin, H., Fulmer, J., Koshlia, V., Fraiz, J., Krakhmalova, O., Fermann, G., Farley, B., Doshi, A., Dhingra, R., Cornell, J., Concha, M., Clark, C., Chang, H., Carman, T., Bidair, M., Bercz, P., Bastani, A., Barney, J., Baker, S., Anderson, C., Amin, M., Almasri, E., Natarajan, I., McCollum, C., MacCallum, P., Davis, M., Body, R., Yagensky, A., Voronkov, L., Vishnivestsky, I., Vakaliuk, I., Ursol, G., Tseluyko, V., Kyrychenko, I., Svyshchenko, Y., Svyridova, I., Ryabichenko, T., Rudenko, L., Reshotko, D., Perepeliuk, M., Parkhomenko, O., Nikonov, V., Maslovaskyi, V., Malynovsky, Y., Sergeeva, E., and Kolman, P.
- Subjects
Male ,medicine.medical_specialty ,Pyridines ,Intracranial Hemorrhages ,030204 cardiovascular system & hematology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Medical illness ,Physiology (medical) ,medicine ,Humans ,030212 general & internal medicine ,Enoxaparin ,Intensive care medicine ,Stroke ,Aged ,business.industry ,Anticoagulants ,Venous Thromboembolism ,medicine.disease ,Thrombosis ,chemistry ,Betrixaban ,Benzamides ,Emergency medicine ,Female ,Cardiology and Cardiovascular Medicine ,business ,Complication ,Venous thromboembolism - Abstract
Background: Stroke is a morbid and potentially mortal complication among patients hospitalized with acute medical illness. The potential of extended-duration thromboprophylaxis with the factor Xa inhibitor betrixaban to reduce the risk of stroke compared with standard-dose enoxaparin in this population was assessed in this retrospective APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Methods: Hospitalized acutely medically ill subjects (n=7513) were randomized in a double-dummy double-blind fashion to either extended-duration oral betrixaban (80 mg once daily for 35–42 days) or standard-dose subcutaneous enoxaparin (40 mg once daily for 10±4 days) for venous thromboprophylaxis. Stroke events were adjudicated by an independent, blinded event adjudication committee. Results: The mean age of study participants was 76 years; 45% were male; 13% had had a stroke; and 45% had congestive heart failure. There were fewer all-cause strokes (0.54% versus 0.97%; relative risk [RR]=0.56; 95% confidence interval, 0.32–0.96; P =0.032; adjusted RR=0.43%; number needed to treat=233) and ischemic strokes (0.48% versus 0.91%; RR=0.53; 95% confidence interval, 0.30–0.94; P =0.026; adjusted RR=0.43%; number needed to treat=233) among patients treated with betrixaban versus enoxaparin through 77 days of follow-up. Among high-risk subjects, those with congestive heart failure or ischemic stroke as their index event, betrixaban reduced the risk of all-cause stroke (0.72% versus 1.48%; RR=0.49; 95% confidence interval, 0.26–0.90; P =0.019; adjusted RR=0.76%; number needed to treat=132) and ischemic stroke (0.63% versus 1.38%; RR=0.45; 95% confidence interval, 0.24–0.87; P =0.014; adjusted RR=0.75%; number needed to treat=134) compared with enoxaparin. Conclusions: Among hospitalized medically ill patients, extended-duration betrixaban significantly reduced all-cause stroke and ischemic stroke through 77 days of follow-up Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01583218.
- Published
- 2017
- Full Text
- View/download PDF
9. P5517Impact of admission during ON vs OFF hours on mortality in unselected ST-elevation myocardial infarction patients referred in percutaneous coronary intervention centers:insights from the ORBI registry
- Author
-
Payot, L, primary, Zabalawi, A, additional, Delaunay, R, additional, Hacot, J P, additional, Lognone, T, additional, Rouault, G, additional, Filippi-Codaccioni, E, additional, Druelles, P H, additional, Didier, R, additional, Gilard, M, additional, Auffret, V, additional, Coudert, I, additional, Cherfaoui, T, additional, Le Guellec, M, additional, and Le Breton, H, additional
- Published
- 2019
- Full Text
- View/download PDF
10. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely III Medical Patients: An APEX Trial Substudy
- Author
-
Gibson, C. M., Korjian, S., Chi, G., Daaboul, Y., Jain, P., Arbetter, D., Goldhaber, S. Z., Hull, R., Hernandez, A. F., Lopes, R. D., Gold, A., Cohen, A. T., Harrington, R. A., Bello, F., Ferrari, A. E., Jure, H., Macin, S., Oliva, M., Parody, M., Poy, C., Baker, R., Colquhoun, D., Coughlin, P., Finfer, S., Hammerschlag, G., Rubinfeld, A., Huber, K., Konig, J., Mathies, R., Pilger, E., Schoenerr, H., Adzerikho, I., Koryk, V., Mikhailova, E., Mitkovskaya, N., Pimanov, S., Polonetsy, L., Soroka, N., Blockmans, D., Delforge, M., Dive, A., Lienart, F., Motte, S., Annichino Bizzacchi, J., Fiss, E., Freire, A., Manenti, E., Ramacciotti, E., Raymuno, S., Rocha, A., Saraiva, J. F., Dimov, B., Grigorov, M., Kalpachki, R., Kamenova, Z., Kostadinova, M., Milanova, M., Mincheva, V., Pencheva, G., Raev, D., Runev, N., Stoeva, N., Stoyanov, M., Syulemzova, S., Todorov, G., Tokmakova, M., Dhar, A., Douketis, J., Kahn, S., Le Gal, G., Pearce, M., Provencher, S., Verreault, S., Arias Alarcon, M., Olivares Canon, C., Opazo Lazcano, M., Potthoff Cardenas, S., Butkovic-Soldo, S., Car, S., Ciglenecki, N., Francetic, I., Jakopovic, M., Kalinic-Grgorinic, H., Knezevic, A., Malojcic, B., Marusic, S., Sikic Vagic, J., Skerk, V., Cermak, O., Cervinka, P., Chlumsky, J., Chochola, J., Cizek, V., Dunaj, M., Dusek, J., Francek, L., Havelka, J., Herold, M., Holaj, R., Horny, I., Hubac, J., Jajtner, P., Kolman, P., Lang, P., Mayer, O., Mikulova, J., Podpera, I., Reiterer, P., Spacek, R., Vejvoda, J., Vyhnanek, M., Christensen, H., Lassen, M., Storgaard, M., Tuxen, C., Urhammer, S., Lember, M., Marandi, T., Uuetoa, T., Airaksinen, J., Honkaniemi, J., Kaaja, R., Lassila, R., Saarinen, J., Tatlisumak, T., Vikman, S., Agraou, B., Aquilanti, S., Belhassane, A., Brisot, D., De Geeter, G., Debourdeau, P., Decoulx, E., El Kouri, D., Falvo, N., Grange, C., Lacroix, P., Messas, E., Mismetti, P., Montaclair, K., Mottier, D., Paleiron, N., Payot, L., Pernod, G., Pottier, P., Proust, A., Quere, I., Roy, P. -M., Schmidt, J., Simoneau, G., Datikashvili-David, I., Khabeishvili, G., Khintibidze, I., Kobulia, B., Megreladze, I., Pagava, Z., Paposhvili, K., Shaburishvili, T., Amann, B., Berrouschot, J., Beyer-Westendorf, J., Blessing, E., Bott, M., Dengler, T., Diehm, C., Dziewas, R., Genth-Zotz, S., Hamann, F., Horacek, T., Klimpe, S., Kroning, R., Lapp, H., Lawall, H., Licka, M., Rizos, T., Schellong, S., Schmidt-Lucke, J., Singer, C., Tiefenbacher, C., Veltkamp, R., Weimar, C., Zeymer, U., Alkonyi, B., Falukozy, J., Futo, L., Katona, A., Kirschner, R., Kristof, P., Lakatos, F., Laszlo, Z., Lupkovics, G., Merkely, B., Nagy Andras, C., Nemeth, L., Papp, A., Soltesz, P., Sudar, Z., Szabo, G., Szegedi, N., Timar, G., Valco, J., Vertes, A., Efrati, S., Elias, M., Gafter, A., Hayek, T., Hussein, O., Lishner, M., Lugassy, G., Zeltser, D., Ageno, W., Cerveri, I., D'Angelo, A., De Pellegrin, A., Imberti, D., Landolfi, R., Lembo, G., Lodigiani, C., Luisetti, M., Moia, M., Molteni, M., Mumoli, N., Novo, S., Orlandini, F., Parisi, R., Pizzini, A., Pomero, F., Salvi, A., Schenone, A., Visona, A., Krievins, D., Martinova, V., Pontaga, N., Rozitis, V., Stukena, I., Alekniene, B., Bagdonas, A., Basijokiene, V., Butkiene, Z., Griskeviciene, V., Naudziunas, A., Norvaisiene, R., Norviliene, R., Petrauskiene, R., Poskiene, R., Susinskiene, D., Valavicius, A., Castillo Leon, R., Cotrina Pereyra, R., Farjardo Karlo, L., Horna, M., Lema Osores, J., Salas, M., Toche Yanez, L., Fryze, W., Gaciong, Z., Gniot, J., Gorecka, D., Gruenpeter, P., Grzelakowski, P., Jastrzebski, D., Kucharski, L., Mirek-Bryniarska, E., Pulkowski, G., Sobkowicz, B., Sulik, P., Tomkowski, W., Walasek, L., Waldemar, K., Wrzesinski, K., Balogh, Z. E., Bojinca, M., Marin, I., Mot, S., Musetescu, R., Podoleanu, C., Popescu, M., Stamate, S., Stanciulescu, G., Vida-Simiti, L., Abashev, A., Andreev, D., Apartsin, K., Arkhipov, M., Averkov, O., Barbarash, O., Belskaya, G., Bogdanov, E., Boldueva, S., Chefranova, Z., Dovgalevskiy, Y., Ershova, O., Goloshchekin, B., Khachatryan, N., Khurs, E., Klein, G., Kobalava, Z., Kosmacheva, E., Kostenko, V., Malygin, A., Martynenko, T., Martynenko, V., Maslova, N., Mordovin, V., Nikolaev, K., Nilk, R., Panchenko, E., Popov, D., Privalova, E., Reshetko, O., Sergeeva, E., Shapovalova, Y., Shpagina, L., Shvarts, Y., Simanenkov, V., Solovyov, O., Vishneva, E., Vishnevskiy, A., Apostolovic, S., Celic, V., Ilic, S., Kovacevic-Kuzmanovic, A., Miloradovic, V., Tan, R. S., Bodikova, S., Cervenakova, A., Dvorak, M., Gaspar, L., Herman, O., Hrubon, A., Kokles, M., Krastev, G., Payer, J., Prokop, D., Spisakova, M., Adler, D., Basson, M., Breedt, J., Engelbrecht, J., Jacobson, B., Mitha, I., Van Dyk, C., Alvarez Sala, L. A., Barbagelata Lopez, C., Bisbe, J., Castro Guardiola, A., Cepeda, J. M., Cereto, F., Diaz Santos, E., Ferrer, R., Gomez Cerezo, J., Gonzales-Porras, J. R., Grandes, J., Jimenez, D., Martin Loeches, I., Mellibovsky, L., Richart, C., Riera, A., Trujillo, J., Vargas Nunez, J. A., Villalta, J., Akgul, O., Guneri, S., Kilichesmez, K., Kirma, C., Kutluk, H., Nazliel, B., Okumus, G., Ongen, G., Tigen, K., Topcuoglu, M., Tuncay, E., Abrahamovych, O., Batushkin, V., Brozhyk, J., Burmak, I., Godlevska, O., Goloborodko, A., Goloborodko, B., Goncharova, Y., Gryb, V., Karpenko, O., Kopytsya, M., Koshlia, V., Krakhmalova, O., Kyrychenko, I., Legkonogov, O., Malynovsky, Y., Maslovaskyi, V., Nikonov, V., Parkhomenko, O., Perepeliuk, M., Reshotko, D., Rudenko, L., Ryabichenko, T., Svyridova, I., Svyshchenko, Y., Tseluyko, V., Ursol, G., Vakaliuk, I., Vishnivestsky, I., Voronkov, L., Yagensky, A., Body, R., Chandra, D., Davis, M., Kesteven, P., Maccallum, P., Mccollum, C., Natarajan, I., Almasri, E., Amin, M., Anderson, C., Baker, S., Barney, J., Bastani, B. B. A., Bercz, P., Bidair, M., Carman, T., Chang, H., Clark, C., Concha, M., Cornell, J., Dhingra, R., Doshi, A., Ebrahimi, R., Farley, B., Fermann, G., Foster, G., Fraiz, J., Fulmer, J., Gaggin, H., Goytia-Leos, D., Hahn, B., Haidar, A., Hamad, A., Hazelrigg, M., Ioachimescu, O., Johnson, B., Kabler, H., Kao, C. -K., Kazimir, M., Kouras, F., Kung, M., Lerner, R., Lopez, J., Macchiavelli, A., Mahal, S., Margolis, B., Mclaren, G., Milling, T., Mittal, M., Nadar, V., Ohaju, V., Ortel, T., Overcash, J., Parthiban, K., Pearl, R., Pineda, L., Pratt, R., Pullman, J., Quintana, O., Rajan, R., Rastogi, P., Rees, C., Rodriguez, W., Saba, F., Shammas, N., Sharma, S., Sokol, S., Stoltz, S., Subich, D., Tuck, M., Updegrove, J., Warner, A., Welch, M., Welker, J., Whitman, B., Wichman, T., Yousef, K., Yusen, R., and Zakai, N.
- Subjects
Male ,pulmonary embolism ,Time Factors ,Pyridines ,Intracranial hemorrhage ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,law.invention ,chemistry.chemical_compound ,0302 clinical medicine ,Randomized controlled trial ,law ,Risk Factors ,Clinical Studies ,Medicine ,030212 general & internal medicine ,Myocardial infarction ,Original Research ,Ischemic stroke ,Hazard ratio ,Absolute risk reduction ,Venous Thromboembolism ,Middle Aged ,Interventional Cardiology ,Pulmonary embolism ,Death ,myocardial infarction ,Treatment Outcome ,Cardiovascular Diseases ,Anesthesia ,Acute Disease ,Benzamides ,Number needed to treat ,Female ,Cardiology and Cardiovascular Medicine ,Intracranial Hemorrhages ,Adult ,venous thromboembolism ,Hemorrhage ,03 medical and health sciences ,Double-Blind Method ,death ,ischemic stroke ,Humans ,Enoxaparin ,Aged ,Proportional Hazards Models ,Inpatients ,Venous thromboembolism ,business.industry ,Settore MED/09 - MEDICINA INTERNA ,Anticoagulants ,Thrombosis ,medicine.disease ,Clinical trial ,chemistry ,Betrixaban ,business ,Acute Coronary Syndromes ,intracranial hemorrhage ,Factor Xa Inhibitors - Abstract
Background Extended‐duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and safety events, one approach to assess net clinical outcomes is to include only those events that are either fatal or cause irreversible harm. Methods and Results This was a post hoc analysis of the APEX trial—a multicenter, double‐blind, randomized controlled trial comparing extended‐duration betrixaban versus standard‐of‐care enoxaparin. A composite of all fatal or irreversible safety (fatal bleeding or intracranial hemorrhage) and efficacy events (cardiopulmonary death, myocardial infarction, pulmonary embolism, and ischemic stroke) was evaluated in a time‐to‐first event analysis. In patients with positive D‐dimer results, betrixaban reduced fatal or irreversible events at 35 to 42 days (4.80% versus 3.54%; hazard ratio, 0.73; absolute risk reduction, 1.26%; number needed to treat, 79 [ P =0.033]) and at study end at 77 days (6.27% versus 4.36%; hazard ratio, 0.70; absolute risk reduction, 1.91%; number needed to treat, 52 [ P =0.005]) versus enoxaparin. In all patients, betrixaban reduced fatal or irreversible events at 35 to 42 days (4.08% versus 2.90%; hazard ratio, 0.71; absolute risk reduction, 1.18%; number needed to treat, 86 [ P =0.006]) and 77 days (5.17% versus 3.64%; hazard ratio, 0.70; absolute risk reduction, 1.53%; number needed to treat, 65 [ P =0.002]). Conclusions Among hospitalized medically ill patients, extended‐duration betrixaban demonstrated an ≈30% reduction in fatal or irreversible ischemic or bleeding events compared with standard‐duration enoxaparin. A total of 65 patients would require treatment with betrixaban to prevent 1 fatal or irreversible event versus enoxaparin. Clinical Trial Registration URL : http://www.ClinicalTrials.gov . Unique identifier: NCT 01583218.
- Published
- 2017
11. Convulsive Seizures Revealing-A Caseous Calcification of the Mitral Annulus (CCMA): A Case Report
- Author
-
R. Delaunay, Payot L, B. Moquet, A. Zabalawi, Joseph Salvador Mingou, and Plurien F
- Subjects
Benign condition ,medicine.medical_specialty ,Pathology ,business.industry ,Caseous necrosis ,medicine.disease ,medicine.anatomical_structure ,Convulsive Seizures ,Mitral valve ,medicine ,Mitral annulus ,Radiology ,Clinical case ,Cardiology and Cardiovascular Medicine ,business ,Stroke ,Calcification - Abstract
Caseous necrosis of the mitral valve ring is a process that is all the more frequently encountered as life expectancy is increased, often by accidental discovery, and is considered as a benign condition, with the responsibility for the clinical symptoms leading to its discovery remains difficult. Through this clinical case, we rediscover the clinical polymorphism of this pathology, the diagnosis of which has been confirmed by the CT scan.
- Published
- 2017
- Full Text
- View/download PDF
12. Implications of Renal Complications In Out Patient Referral for Coronary Angiography: Prospective Observational Study of 98 Cases
- Author
-
A. Zabalawi, R. Delaunay, C. Oueslati, B. Moquet, Joseph Salvador Mingou, and Payot L
- Subjects
education.field_of_study ,Pediatrics ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Population ,Acute kidney injury ,Renal function ,medicine.disease ,Nephropathy ,Surgery ,Ambulatory care ,medicine ,Risk factor ,Cardiology and Cardiovascular Medicine ,education ,business ,Prospective cohort study ,Dialysis - Abstract
The incidence of acute kidney failure remains high, due to the multiplication of interventional procedures on subjects at risk. It increases both morbi-mortality in hospitals and in the long term. The identification of patients atriskis primordial in order to implement the preventiv emeasures, whose expansion remains the ‘gold standard’. The realization of a coronary angiography in ambulatory care in this type of patient at risk is possible without increasing renal morbidity, under the cover of a good hydration. Introduction: Acute renal failure is a complication that remains common after injection of contrast agent. It increases both morbidity and hospital mortality in the long term. We wanted to carry out a prospective observational study to evaluate the incidence of renal complications (acute renal failure, dialysis) of patients referred as an outpatient in our center for coronary angiography and who have benefited from measures of prevention of renal toxicity as recommended by learned societies. Methodology: We conducted a prospective study at the Yves Le Foll hospital in Saint Brieuc over a period of 4 months from November 2015 to February 2016, in patients admitted on an outpatient basis for coronary angiography who had previously suspended all drugs with nephrotoxic potential and with hydration surrounding the examination. A survey card was developed to collect, after informed consent, sociodemographic data, risk factors, comorbidities, clinical and paraclinical data. All data was entered and analyzed using SPSS software version 18.0. Results: Ninety-eight patients had an ambulatory coronary angiogram during this period. The sex ratio was 3.66 in favor of the male genus with an average age of 65 years. Three-quarters of the population (71%) had at least one risk factor for contrast-induced nephropathy. The mean clearance values before and after coronary angiography were almost similar (80 μmol/l) without significant variation. No impairment of renal function was observed in patients at risk regardless of the amount of contrast injected (range: between 30 and 277 ml). When patients accumulate risk factors for induced nephropathy in the contrast medium, there is an increase in the blood creatinine level with the number of factors but no significant change (p: 0.24) of renal function after iodine injection. Conclusion: The incidence of acute kidney injury remains high, due to the increase of intervention procedures in subjects at risk. The identification of these patients at risk is paramount in order to implement the preventive measures of which volume expansion remains the gold standard. The realization of an outpatient coronary angiography in this type of patient at risk is feasible without increasing renal morbidity with a good hydration.
- Published
- 2017
- Full Text
- View/download PDF
13. Prinzmetal or Vasospastic Angina in a Young Woman: An Under-Diagnosed Pathology
- Author
-
Payot L, R. Delaunay, Maboury Diao, Momar Dioum, Adama Kane, Fatou Aw, A. Zabalawi, Ndiaye Mb, Serigne Abdou Ba, Diack B, Joseph Salvador Mingou, and Ndao Sct
- Subjects
Coronary angiography ,medicine.medical_specialty ,Vasospastic angina ,Poor prognosis ,medicine.diagnostic_test ,business.industry ,Omics ,Surgery ,Internal medicine ,Angiography ,medicine ,Cardiology ,Clinical case ,Cardiology and Cardiovascular Medicine ,business ,Challenge tests - Abstract
Vasospastic angina is considered rare but its prevalence is probably underestimated, especially in the case of atheromatous coronary lesions. Its diagnosis remains important because of its poor prognosis and its therapeutic features. We report a clinical case illustrating the issue of vasospastic angina’s diagnosis. Diagnostic ways such as coronary spasm challenge tests must be adapted to the evolution of the techniques and the use of coronary angiography nowadays, in particular the preferential use of the radial pathway especially in women with a smaller radial caliber compared to men.
- Published
- 2017
- Full Text
- View/download PDF
14. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial
- Author
-
Raymuno, S., Ramacciotti, E., Manenti, E., Freire, A., Fiss, E., Bizzacchi, J. Annichino, Lienart, F., Dive, A., Delforge, M., Blockmans, D., Soroka, N., Kamenova, Z., Kostadinova, M., Milanova, M., Pencheva, G., Runev, N., Stoeva, N., Stoyanov, M., Syulemzova, S., Todorov, G., Polonetsy, L., Pimanov, S., Mitkovskaya, N., Tokmakova, M., Dhar, A., Mikhailova, E., Koryk, V., Adzerikho, I., Schoenerr, H., Mathies, R., Douketis, J., Konig, J., Le Gal, G., Pearce, M., Provencher, S., Verreault, S., Alarcon, M. Arias, Lazcano, M. Opazo, Cardenas, S. Potthoff, Butkovic-Soldo, S., Car, S., Ciglenecki, N., Francetic, I., Jakopovic, M., Kalinic-Grgorinic, H., Knezevic, A., Marusic, S., Vagic, J. Sikic, Skerk, V., Cermak, O., Gibson, C. Michael, Halaby, Rim, Korjian, Serge, Daaboul, Yazan, Arbetter, Douglas F., Yee, Megan K., Chlumsky, J., Chochola, J., Cizek, V., Goldhaber, Samuel Z., Hull, Russel, Hernandez, Adrian F., Huber, K., Lu, Shiao-ping, Dunaj, M., Dusek, J., Francek, L., Havelka, J., Herold, M., Holaj, R., Nazliel, BİJEN, Bandman, Olga, Leeds, Janet M., Gold, Alex, Harrington, Robert A., Bello, F., Ferrari, A. E., Jure, H., Macin, S., Oliva, M., Parody, M., Horny, I., Hubac, J., Jajtner, P., Kolman, P., Poy, C., Baker, R., Lang, P., Mikulova, J., Podpera, I., Reiterer, P., Spacek, R., Vejvoda, J., Vyhnanek, M., Christensen, H., Lassen, M., Storgaard, M., Tuxen, C., Urhammer, S., Lember, M., Uuetoa, T., Airaksinen, J., Honkaniemi, J., Kaaja, R., Saarinen, J., Tatlisumak, T., Vikman, S., Agraou, B., Aquilanti, S., Belhassane, A., Brisot, D., De Geeter, G., Coughlin, P., Finfer, S., Debourdeau, P., Decoulx, E., El Kouri, D., Falvo, N., Grange, C., Rubinfeld, A., Lacroix, P., Messas, E., Mismetti, P., Montaclair, K., Paleiron, N., Payot, L., Zakai, N., Yousef, K., Wichman, T., Whitman, B., Welker, J., Welch, M., Warner, A., Updegrove, J., Tuck, M., Stoltz, S., Sokol, S., Sharma, S., Shammas, N., Saba, F., Rodriguez, W., Rastogi, P., Rajan, R., Quintana, O., Pullman, J., Pratt, R., Pineda, L., Pernod, G., Pearl, R., Parthiban, K., Ortel, T., Ohaju, V., Pottier, P., Proust, A., Quere, I., Roy, P-M., Schmidt, J., Simoneau, G., Datikashvili-David, I., Khabeishvili, G., Khintibidze, I., Nadar, V., Mittal, M., Milling, T., McLaren, G., Margolis, B., Mahal, S., Macchiavelli, A., Lopez, J., Lerner, R., Kung, M., Kouras, F., Kazimir, M., Kao, C-K., Kabler, H., Ioachimescu, O., Hazelrigg, M., Hamad, A., Haidar, A., Hahn, B., Goytia-Leos, D., Gaggin, H., Fulmer, J., Fraiz, J., Fermann, G., Farley, B., Doshi, A., Dhingra, R., Cornell, J., Concha, M., Clark, C., Chang, H., Carman, T., Bidair, M., Bercz, P., Bastani, A., Barney, J., Baker, S., Anderson, C., Amin, M., Almasri, E., Natarajan, I., McCollum, C., MacCallum, P., Davis, M., Body, R., Yagensky, A., Voronkov, L., Vishnivestsky, I., Vakaliuk, I., Ursol, G., Tseluyko, V., Svyshchenko, Y., Svyridova, I., Ryabichenko, T., Rudenko, L., Reshotko, D., Perepeliuk, M., Parkhomenko, O., Nikonov, V., Maslovaskyi, V., Malynovsky, Y., Legkonogov, O., Kyrychenko, I., Krakhmalova, O., Koshlia, V., Kopytsya, M., Karpenko, O., Gryb, V., Goncharova, Y., Goloborodko, B., Goloborodko, A., Godlevska, O., Burmak, I., Brozhyk, J., Batushkin, V., Abrahamovych, O., Tuncay, E., Topcuoglu, M., Tigen, K., Okumus, G., Kutluk, H., Kirma, C., Kilichesmez, K., Guneri, S., Akgul, O., Villalta, J., Vargas Nunez, J. A., Trujillo, J., Riera, A., Richart, C., Mellibovsky, L., Jimenez, D., Grandes, J., Gonzales-Porras, J. R., Gomez Cerezo, J., Ferrer, R., Diaz Santos, E., Cereto, F., Cepeda, J. M., Castro Guardiola, A., Bisbe, J., Barbagelata Lopez, C., Alvarez Sala, L. A., Van Dyk, C., Mitha, I., Engelbrecht, J., Breedt, J., Basson, M., Adler, D., Spisakova, M., Payer, J., Krastev, G., Kokles, M., Hrubon, A., Herman, O., Dvorak, M., Cervenakova, A., Bodikova, S., Miloradovic, V., Kovacevic-Kuzmanovic, A., Ilic, S., Celic, V., Apostolovic, S., Vishnevskiy, A., Vishneva, E., Solovyov, O., Simanenkov, V., Shvarts, Y., Shpagina, L., Shapovalova, Y., Sergeeva, E., Reshetko, O., Privalova, E., Popov, D., Nilk, R., Nikolaev, K., Mordovin, V., Maslova, N., Martynenko, V., Martynenko, T., Malygin, A., Kostenko, V., Kosmacheva, E., Kobalava, Z., Klein, G., Khachatryan, N., Ershova, O., Dovgalevskiy, Y., Chefranova, Z., Boldueva, S., Bogdanov, E., Belskaya, G., Barbarash, O., Averkov, O., Arkhipov, M., Apartsin, K., Andreev, D., Abashev, A., Vida-Simiti, L., Stanciulescu, G., Stamate, S., Kobulia, B., Megreladze, I., Pagava, Z., Paposhvili, K., Amann, B., Beyer-Westendorf, J., Blessing, E., Bott, M., Dengler, T., Dziewas, R., Genth-Zotz, S., Hamann, F., Horacek, T., Klimpe, S., Kroning, R., Lapp, H., Lawall, H., Licka, M., Rizos, T., Tiefenbacher, C., Weimar, C., Alkonyi, B., Falukozy, J., Futo, L., Katona, A., Kirschner, R., Kristof, P., Lakatos, F., Lupkovics, G., Merkely, B., Andras, C. Nagy, Nemeth, L., Papp, A., Soltesz, P., Sudar, Z., Szabo, G., Szegedi, N., Timar, G., Valco, J., Vertes, A., Efrati, S., Elias, M., Gafter, A., Hayek, T., Hussein, O., Lishner, M., Lugassy, G., Cerveri, I., D'Angelo, A., De Pellegrin, A., Imberti, D., Landolfi, R., Lembo, G., Lodigiani, C., Moia, M., Molteni, M., Mumoli, N., Novo, S., Orlandini, F., Parisi, R., Pizzini, A., Pomero, F., Salvi, A., Schenone, A., Visona, A., Martinova, V., Pontaga, N., Rozitis, V., Stukena, I., Alekniene, B., Basijokiene, V., Butkiene, Z., Griskeviciene, V., Naudziunas, A., Norvaisiene, R., Norviliene, R., Petrauskiene, R., Poskiene, R., Susinskiene, D., Valavicius, A., Castillo Leon, R., Pereyra, R. Cotrina, Karlo, L. Farjardo, Horna, M., Salas, M., Yanez, L. Toche, Fryze, W., Gaciong, Z., Gniot, J., Gorecka, D., Gruenpeter, P., Grzelakowski, P., Jastrzebski, D., Kucharski, L., Mirek-Bryniarska, E., Pulkowski, G., Sobkowicz, B., Sulik, P., Walasek, L., Waldemar, K., Wrzesinski, K., Balogh, Z. E., Bojinca, M., Marin, I., Musetescu, R., Podoleanu, C., Popescu, M., Kalpachki, R., Grigorov, M., Dimov, B., Rocha, A., Goloshchekin, B., Berrouschot, J., Laszlo, Z., Rees, C., Overcash, J., Prokop, D., and Cohen, Alexander T.
- Subjects
Relative risk reduction ,Male ,Pyridines ,Population ,Hemorrhage ,030204 cardiovascular system & hematology ,law.invention ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Pharmacokinetics ,Randomized controlled trial ,Double-Blind Method ,law ,Medicine ,Humans ,030212 general & internal medicine ,Dosing ,Enoxaparin ,education ,Aged ,Aged, 80 and over ,Venous Thrombosis ,education.field_of_study ,business.industry ,Absolute risk reduction ,Anticoagulants ,Venous Thromboembolism ,Hospitalization ,chemistry ,Concomitant ,Betrixaban ,Anesthesia ,Benzamides ,Female ,Cardiology and Cardiovascular Medicine ,business ,Pulmonary Embolism ,Factor Xa Inhibitors - Abstract
The APEX trial assessed the safety and efficacy of extended-duration thromboprophylaxis using betrixaban versus standard dosing of enoxaparin among hospitalized, acutely ill medical patients. The 80-mg betrixaban dose was halved to 40 mg among subjects with severe renal insufficiency and those receiving a concomitant strong P-glycoprotein inhibitor.This analysis assessed the pharmacokinetics, efficacy, and safety of full- (80 mg) and reduced-dose (40 mg) betrixaban relative to enoxaparin in the APEX trial.The median concentration of betrixaban among subjects administered the 80-mg dose was higher than that of the 40-mg dose (19 ng/mL vs 11 ng/mL, P.001). In the primary analysis cohort 1 (d-dimer ≥2× upper limit of normal), the primary efficacy outcome (asymptomatic proximal deep vein thrombosis, symptomatic proximal or distal deep vein thrombosis, symptomatic nonfatal pulmonary embolism, or venous thromboembolism-related death) was significantly reduced among subjects treated with 80 mg of extended-duration betrixaban versus enoxaparin (6.27% [95/1516] vs 8.39% [130/1549], relative risk reduction=0.26 [0.04-0.42], P=.023), and similarly in the entire primary efficacy outcome population (4.87% [122/2506] vs 7.06% [181/2562], relative risk reduction=0.30 [0.13-0.44], P=.001). There was no difference in the primary outcome for subjects treated with 40 mg betrixaban vs enoxaparin across cohorts. In addition, there was no excess of major bleeding associated with either betrixaban dose compared with enoxaparin.The 80-mg betrixaban dose achieves higher plasma concentrations than the 40-mg dose and, in contrast to the 40-mg dose, is associated with improved efficacy across all cohorts relative to standard-dose enoxaparin without an excess risk of major bleeding in the management of medically ill subjects.
- Published
- 2016
15. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients
- Author
-
Engelbrecht, J., Finfer, S., Van Dyk, C., Cohen, Alexander, Grandes, J., Cepeda, J. M., NAZLIEL, BİJEN, Cohen, Alexander T., Efrati, S., Zakai, N., Yousef, K., Wichman, T., Whitman, B., Welker, J., Welch, M., Warner, A., Updegrove, J., Tuck, M., Stoltz, S., Sokol, S., Sharma, S., Shammas, N., Saba, F., Rodriguez, W., Rees, C., Rastogi, P., Rajan, R., Quintana, O., Pullman, J., Pratt, R., Pineda, L., Pearl, R., Parthiban, K., Overcash, J., Ortel, T., Ohaju, V., Nadar, V., Mittal, M., Milling, T., McLaren, G., Margolis, B., Mahal, S., Macchiavelli, A., Lopez, J., Lerner, R., Kung, M., Kouras, F., Kazimir, M., Kao, C-K., Kabler, H., Ioachimescu, O., Hazelrigg, M., Hamad, A., Haidar, A., Hahn, B., Goytia-Leos, D., Gaggin, H., Fulmer, J., Fraiz, J., Fermann, G., Farley, B., Doshi, A., Dhingra, R., Cornell, J., Concha, M., Clark, C., Chang, H., Carman, T., Bidair, M., Bercz, P., Bastani, A., Barney, J., Baker, S., Anderson, C., Amin, M., Almasri, E., Natarajan, I., McCollum, C., MacCallum, P., Davis, M., Body, R., Yagensky, A., Voronkov, L., Vishnivestsky, I., Vakaliuk, I., Ursol, G., Tseluyko, V., Svyshchenko, Y., Svyridova, I., Ryabichenko, T., Rudenko, L., Alekniene, B., Reshotko, D., Perepeliuk, M., Parkhomenko, O., Nikonov, V., Maslovaskyi, V., Malynovsky, Y., Legkonogov, O., Kyrychenko, I., Krakhmalova, O., Koshlia, V., Kopytsya, M., Karpenko, O., Gryb, V., Goncharova, Y., Goloborodko, B., Goloborodko, A., Godlevska, O., Burmak, I., Brozhyk, J., Batushkin, V., Abrahamovych, O., Tuncay, E., Topcuoglu, M., Tigen, K., Okumus, G., Kutluk, H., Kirma, C., Kilichesmez, K., Guneri, S., Akgul, O., Villalta, J., Vargas Nunez, J. A., Trujillo, J., Riera, A., Richart, C., Mellibovsky, L., Jimenez, D., Gonzales-Porras, J. R., Gomez Cerezo, J., Ferrer, R., Diaz Santos, E., Cereto, F., Castro Guardiola, A., Bisbe, J., Barbagelata Lopez, C., Alvarez Sala, L. A., Mitha, I., Breedt, J., Basson, M., Adler, D., Spisakova, M., Prokop, D., Payer, J., Krastev, G., Kokles, M., Hrubon, A., Herman, O., Dvorak, M., Cervenakova, A., Bodikova, S., Miloradovic, V., Kovacevic-Kuzmanovic, A., Ilic, S., Celic, V., Apostolovic, S., Vishnevskiy, A., Vishneva, E., Solovyov, O., Simanenkov, V., Shvarts, Y., Shpagina, L., Shapovalova, Y., Sergeeva, E., Reshetko, O., Privalova, E., Popov, D., Nilk, R., Nikolaev, K., Mordovin, V., Maslova, N., Martynenko, V., Martynenko, T., Malygin, A., Kostenko, V., Kosmacheva, E., Kobalava, Z., Klein, G., Khachatryan, N., Goloshchekin, B., Ershova, O., Dovgalevskiy, Y., Chefranova, Z., Boldueva, S., Bogdanov, E., Belskaya, G., Barbarash, O., Averkov, O., Arkhipov, M., Apartsin, K., Andreev, D., Abashev, A., Vida-Simiti, L., Stanciulescu, G., Stamate, S., Harrington, Robert A., Goldhaber, Samuel Z., Hull, Russell D., Popescu, M., Wiens, Brian L., Gold, Alex, Hernandez, Adrian F., Gibson, C. Michael, Harrington, Robert, Hull, Russell, Goldhaber, Samuel, Hernandez, Adrian, Ceresetto, Jose Manuel, Colquhoun, David, Pilger, Ernst, Polonetsky, Leonid, Podoleanu, C., Musetescu, R., Marin, I., Bojinca, M., Motte, Serge, Saraiva, Jose Francisco, Balogh, Z. E., Wrzesinski, K., Waldemar, K., Walasek, L., Raev, Dimitar, Mincheva, Valentina, Kahn, Susan, Sulik, P., Canon, Claudia Olivares, Malojcic, Branko, Mayer, Otto, Husted, Steen, Marandi, Toomas, Lassila, Riitta, Mottier, Dominique, Shaburishvili, Tamaz, Bauersachs, Rupert, Zeymer, Uwe, Hajko, Erik, Sobkowicz, B., Zeltser, David, Ageno, Walter, Krievins, Dainis, Bagdonas, Alfredas, Osores, Juan Lema, Tomkowski, Witold, Mot, Stefan, Panchenko, Elizaveta, Tan, Ru San, Gaspar, Ludovit, Jacobson, Barry, Monreal, Manuel, Ongen, Gul, Parkhomenko, Alexander, Uprichard, James, Pulkowski, G., Mirek-Bryniarska, E., Kucharski, L., Jastrzebski, D., Yusen, Roger, Grzelakowski, P., Merli, Geno, Gruenpeter, P., Gorecka, D., Gniot, J., Gaciong, Z., Fryze, W., Peacock, Frank, Schellong, Sebastian, Januzzi, James, Piovella, Franco, Cochet, Madeleine, Michalak, Nathan, Stepanchak, Maria, Spielman, Kathryn, Neal, Brandon, Florea, Ana, Chi, Gerald, Szlosek, Donald, Jain, Purva, Popma, Christopher, Korjian, Serge, Daaboul, Yazan, Halaby, Rim, Yanez, L. Toche, Lemor, Alejandro, Zacarkim, Marcelo, Romero, Gonzalo, Hernandez Elenes, Jesus Rosario, Alvarado, Alonso, Susheela, Ammu, Leitao, Meghan, Salas, M., Bandman, Olga, Horna, M., Strumph, Peter, Vinh, Nancy, Visona, A., Kostadinova, M., Vance, Annemarie, Moia, M., Wiens, Brian, Orlandini, F., Parisi, R., Pontaga, N., Smoak, Carey, Storgaard, M., Molteni, M., Castelino, Rennie, Goodman, Shelly, Stukena, I., Leeds, Janet, al-Khalidi, Hussein, Milanova, M., Karlo, L. Farjardo, Leimberger, Jeffrey, Phillips, Thomas, Rizos, T., Pencheva, G., Pomero, F., Francis, Charles, Novo, S., Pereyra, R. Cotrina, Tiefenbacher, C., Buller, Harry, Roberts, Robin, Prins, Martin, Weimar, C., Tuxen, C., Urhammer, S., Lember, M., Runev, N., Uuetoa, T., Spyropoulos, Alex, Carrier, Marc, Alkonyi, B., Lopes, Renato D., Horacek, T., Airaksinen, J., Honkaniemi, J., Pottier, P., Falukozy, J., Kaaja, R., Stoeva, N., Saarinen, J., Stoyanov, M., Pizzini, A., Devor, Adam, Tatlisumak, T., Kolls, Bradley, Dedrick, Joseph, Todd, Jamie, Jones, William Schuyler, Vikman, S., Agraou, B., Futo, L., Castillo Leon, R., Eapen, Zubin, Katona, A., Proust, A., Quere, I., Kirschner, R., Syulemzova, S., Valavicius, A., Todorov, G., Tokmakova, M., Dhar, A., Klimpe, S., Ahmad, Tariq, Brenna, J. Matthew, Douketis, J., Le Gal, G., Pearce, M., Susinskiene, D., Brito, Flavio, Provencher, S., Rozitis, V., Roy, P-M., Kroning, R., Gulack, Brian, Schmidt, J., Meza, James, Parikh, Kishan, Cooper, Lauren, Poskiene, R., Aquilanti, S., Lapp, H., Kristof, P., Lakatos, F., Laszlo, Z., Belhassane, A., Petrauskiene, R., Pagidipati, Neha, Simoneau, G., Verreault, S., Guimaraes, Patricia, Brisot, D., Perkins, Lynn M., De Geeter, G., Debourdeau, P., Alarcon, M. Arias, Lupkovics, G., Norviliene, R., Wilson, Matthew, Merkely, B., Lazcano, M. Opazo, Collier, Jeannie, Andras, C. Nagy, Cardenas, S. Potthoff, Butkovic-Soldo, S., Norvaisiene, R., Decoulx, E., Hayden, Nikieia, El Kouri, D., Car, S., Nemeth, L., Leizorovicz, Alain, Ciglenecki, N., Naudziunas, A., Datikashvili-David, I., Francetic, I., Jakopovic, M., Becker, Francois, Jennings, Lisa, Khabeishvili, G., Bello, F., Ferrari, A. E., Jure, H., Macin, S., Griskeviciene, V., Kalinic-Grgorinic, H., Falvo, N., Khintibidze, I., Grange, C., Kobulia, B., Knezevic, A., Megreladze, I., Marusic, S., Papp, A., Pagava, Z., Lawall, H., Oliva, M., Paposhvili, K., Parody, M., Amann, B., Soltesz, P., Sudar, Z., Butkiene, Z., Szabo, G., Vagic, J. Sikic, Szegedi, N., Poy, C., Timar, G., Skerk, V., Cermak, O., Valco, J., Baker, R., Coughlin, P., Vertes, A., Rubinfeld, A., Elias, M., Berrouschot, J., Gafter, A., Hayek, T., Chlumsky, J., Lacroix, P., Messas, E., Chochola, J., Cizek, V., Basijokiene, V., Hussein, O., Dunaj, M., Dusek, J., Huber, K., Lishner, M., Lugassy, G., Cerveri, I., D'Angelo, A., De Pellegrin, A., Francek, L., Havelka, J., Konig, J., Beyer-Westendorf, J., Herold, M., Holaj, R., Imberti, D., Landolfi, R., Blessing, E., Mathies, R., Schoenerr, H., Adzerikho, I., Koryk, V., Licka, M., Martinova, V., Horny, I., Mikhailova, E., Mitkovskaya, N., Pimanov, S., Polonetsy, L., Soroka, N., Blockmans, D., Delforge, M., Dive, A., Lienart, F., Bizzacchi, J. Annichino, Fiss, E., Mismetti, P., Freire, A., Hubac, J., Jajtner, P., Manenti, E., Ramacciotti, E., Lembo, G., Raymuno, S., Rocha, A., Kolman, P., Lang, P., Bott, M., Dengler, T., Mikulova, J., Dimov, B., Podpera, I., Reiterer, P., Dziewas, R., Montaclair, K., Genth-Zotz, S., Hamann, F., Paleiron, N., Spacek, R., Payot, L., Vejvoda, J., Vyhnanek, M., Christensen, H., Salvi, A., Lodigiani, C., Pernod, G., Grigorov, M., Lassen, M., Mumoli, N., Kalpachki, R., Kamenova, Z., Schenone, A., Guy's and St Thomas' Hospital [London], Stanford Medicine, Stanford University, Brigham and Women's Hospital [Boston], Thrombosis Research Unit, University of Calgary, Portola Pharmaceuticals (Portola), PORTOLA PHARMACEUTICALS, Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute (DCRI - DURHAM), Duke University [Durham], Beth Israel Deaconess Medical Center [Boston, USA], Harvard Medical School [Boston] (HMS), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO)-Université de Brest (UBO), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), and Université de Brest (UBO)-Université de Brest (UBO)
- Subjects
Male ,Pyridines ,Medizin ,030204 cardiovascular system & hematology ,law.invention ,chemistry.chemical_compound ,0302 clinical medicine ,Randomized controlled trial ,Risk Factors ,law ,030212 general & internal medicine ,ComputingMilieux_MISCELLANEOUS ,Ultrasonography ,Venous Thrombosis ,Factors de risc en les malalties ,Medicine (all) ,Acute Disease ,Adult ,Aged ,Benzamides ,Double-Blind Method ,Drug Administration Schedule ,Factor Xa Inhibitors ,Female ,Fibrin Fibrinogen Degradation Products ,Hemorrhage ,Hospitalization ,Humans ,Middle Aged ,Pulmonary Embolism ,Venous Thromboembolism ,General Medicine ,3. Good health ,Pulmonary embolism ,Venous thrombosis ,Cohort ,medicine.medical_specialty ,Patients ,Risk factors in diseases ,Placebo ,03 medical and health sciences ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Internal medicine ,Thromboembolism ,medicine ,Pacients ,Betrixaban ,Thromboprophylaxis ,Acutely Ill Medical Patients ,Tromboembolisme ,business.industry ,Settore MED/09 - MEDICINA INTERNA ,ta3121 ,Population cohort ,medicine.disease ,Surgery ,chemistry ,Once daily ,business - Abstract
Background\ud Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown.\ud \ud Methods\ud Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days. We performed sequential analyses in three prespecified, progressively inclusive cohorts: patients with an elevated d-dimer level (cohort 1), patients with an elevated d-dimer level or an age of at least 75 years (cohort 2), and all the enrolled patients (overall population cohort). The statistical analysis plan specified that if the between-group difference in any analysis in this sequence was not significant, the other analyses would be considered exploratory. The primary efficacy outcome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism. The principal safety outcome was major bleeding.\ud \ud Results\ud A total of 7513 patients underwent randomization. In cohort 1, the primary efficacy outcome occurred in 6.9% of patients receiving betrixaban and 8.5% receiving enoxaparin (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 0.65 to 1.00; P=0.054). The rates were 5.6% and 7.1%, respectively (relative risk, 0.80; 95% CI, 0.66 to 0.98; P=0.03) in cohort 2 and 5.3% and 7.0% (relative risk, 0.76; 95% CI, 0.63 to 0.92; P=0.006) in the overall population. (The last two analyses were considered to be exploratory owing to the result in cohort 1.) In the overall population, major bleeding occurred in 0.7% of the betrixaban group and 0.6% of the enoxaparin group (relative risk, 1.19; 95% CI, 0.67 to 2.12; P=0.55).\ud \ud Conclusions\ud Among acutely ill medical patients with an elevated d-dimer level, there was no significant difference between extended-duration betrixaban and a standard regimen of enoxaparin in the prespecified primary efficacy outcome. However, prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts. (Funded by Portola Pharmaceuticals; APEX ClinicalTrials.gov number, NCT01583218. opens in new tab.)
- Published
- 2016
- Full Text
- View/download PDF
16. Évolution des délais et de la prise en charge interventionnelle de l’infarctus du myocarde avec sus décalage du ST à la phase aiguë entre 2007 et 2014
- Author
-
A. Zabalawi, R. Delaunay, Payot L, C. Oueslati, and B. Moquet
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,medicine ,Cardiology and Cardiovascular Medicine ,business - Abstract
Introduction La prise en charge des infarctus du myocarde aigus avec sus-decalage du segment ST (IDM avec ST+) necessite une reperfusion en urgence. Les delais et les modalites de prise en charge pre- et intra-hospitaliere evoluent avec le temps. Nous avons examine cette evolution. Materiel et methodes Etude monocentrique retrospective comparant les des delais de reperfusion et les techniques interventionnelles des patients admis pour un IDM avec ST+ a la phase aigue ( Resultats Trois cent neuf patients ont ete inclus (120 patients en 2007, 189 patients en 2014). L’âge moyen (± DS) etait de 62,6 (± 14,3) ans en 2007 et 63,9 (± 12,8) ans en 2014. On note une preponderance masculine ; 74,2 % d’hommes en 2007 et 79,9 % en 2014. On rapporte un recours plus frequent au centre 15 comme destinataire du premier appel : 40 % en 2007 et a 53 % en 2014. Neanmoins, il persiste une proportion non negligeable et stable dans le temps de patients qui n’ont pas le reflexe d’appeler le SAMU ou les pompiers (32 % en 2007 et 35 % en 2014). Trente patients ont ete thrombolyses (25 %) en 2007 contre 19 (10,1 %) en 2014. On rapporte une baisse significative du delai entre le debut des symptomes et l’admission des patient : delai median de 210 min en 2007 et 160 min en 2014 ; p = 0,02. En angioplastie primaire (ATL), on a note une baisse significative de la plupart des delais (delai 1er appel-ATL ; p = 0,04, delai 1er appel–admission ; p = 0,006, delai admission–ballon ; p = 0,015, delai 1re intervention–admission ; p = 0,006, delai 1re intervention–ATL ; p = 0,01). La coronarographie a ete realisee par voie femorale pour 93,9 % des patients en 2007 contre 18,1 % en 2014 (81,9 % par voie radiale en 2014). Une angioplastie immediate a ete realisee dans 77,5 % en 2007 et 90,5 % des patients en 2014. L’utilisation de la thromboaspiration mecanique et celle des stents actifs ont significativement augmente entre les deux periodes (26,5 % en 2007 versus 68,8 % en 2014) et (0,1 % versus 33,5 %) respectivement ; p = 0,0001 pour les deux items. Le recours aux antiGPIIb/IIIa etait beaucoup plus large en 2007 comparativement a 2014 (70,8 % contre 21,7 % respectivement ; p = 0,0001). Conclusion Cette etude comparative entre 2007 et 2014 montre une reduction significative des delais de prise en charge, un recours moins frequent a la thrombolyse comme therapeutique de reperfusion, une progression importante de la voie radiale, de l’implantation de stents actifs et de l’utilisation de la thromboaspiration.
- Published
- 2016
- Full Text
- View/download PDF
17. Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry
- Author
-
Fauchier, L., Greenlaw, N., Ferrari, R., Ford, I., Fox, K. M., Tardif, J. -C., Tendera, M., Steg, P. G., Sokn, F. J., Reid, C., Lang, I., Van den Branden, F., Cesar, L. M., Mattos, M. A., Nazar Luqman, H., Goudev, A., Dorian, P., Hu, D., Widimsky, P., Hassager, C., Danchin, N., Kaab, S., Vardas, P., Sulaiman, K. J., Al Mahmeed, W., Al Suwaidi, J., Al Rashdan, I., Abdulkader, F., Merkely, B., Kaul, U., Daly, K., Tavazzi, L., Jang, Y., Erglis, A., Laucevicius, A., Jamaluddin, A. N., Gamba, M. A., Tulevski, I. I., Stepinska, J., Morais, J., Macarie, C., Oganov, R., Shalnova, S., Al-Zaibag, M., Hou, M. K., Kamensky, G., Fras, Z., Kanic, V., Naidoo, D. P., Zamorano, J. L., Rickli, H., Jaussi, A., Sriratanasathavorn, C., Kalra, P., Lutai, M., Oleksandr, Nguyen, L. V., Henry, R., Ahuad Guerrero, A., Basara, M., Belcastro, F., Bertarini, J. A., Cazenave, C., Dreycopp, H., Egido, J., Estrella, J., Garofalo, D., Giordano, J., Lagioia, H., Lago, N., La Greca, R., Lema, L., Lopez Cabanillas, N., Luquez, H., Miller, C., Prada, E., Rodenas, P., Schena, R. G., Suarez, G., Tomatti, A., Colquhoun, D. M., Conradie, A., Cox, S., Cross, D., Fathi, R., Fitzgerald, B., Hamilton-Craig, I., Holt, G., Jayasinghe, S. R., Mai, N., Moolman, J., Motyer, R. A., Phillips, K., Rafter, A., Rahman, A., Rainbird, A., Scalia, G., Taylor, A., West, P., Alford, K., Amor, R., Astridge, P., Bastian, B., Bates, F., Doohan, M. M., Du Plooy, J., Ford, J. C., Kanagaratnam, L., Khoury, V., Parkin, R., Rogers, J., Sceats, G., Waldman, A., Wang, D., Wright, S., Ardill, J., Aylward, P., Beltrame, J. F., Bradley, J., Heddle, W., Joseph, M., Rajendran, S., Varughese, S., Brice, E., Hockings, B., Janssen, J., Kozlowski, A., O'Shea, J., Playford, D. A., Woollard, K., Ajani, A., Barron, G., Better, N., Chan, B., Chan, R., Cotroneo, J., Counsell, J. T., Eccleston, D. S., Forge, B. H. R., Hamer, A., Horrigan, M., Jelinek, V. M. J., Lew, R., O'Donnell, D., Panetta, F., Sebastian, M., Soward, A., Srivastava, P., Strathmore, N. F., Sylivris, S., Szto, G., Veth, V., Yip, T., Badr-Eslam, R., Kleemann, L., Steurer, G., Morz-Proszowski, B., Auhser, F., Teleky, U., Sepp, G., Beinhauer, A., Kero, D., Lavicka, C., Perger, T., Hadjiivanov, V., Feldner-Busztin, M., Mika, R., Filip, W., Mahr, A., Toplak, J., Millauer, M. G., Haralambus, P., Walcher, K., Karner, K. H., Ziak, E., Painsipp, P., Frank, U., Suntinger, A., Gritsch, W., Bode, G., Herrmann, R., Raffelsberger, R., Topf, H., Moser, E., Fochterle, J., Honsig, T., Mayr, K., Mayr, H., Kaserbacher, R., Dzien, A., Galehr, E., Felbermayer, M., Schwarz, R., Amini, R., Appeltants, H., Ballet, A., Bar, J. -P., Beckers, J., Bergen, J. -M., Berkenboom, G., Bernard, X., Bouvy, T., Briki, R., Claeys, M., Dascotte, Y., Davin, L., De Backer, T., De Keyser, F., De Meester, A., De Ridder, S., Dendale, P., Denef, K., Dhondt, E., Emonts, M., Geraedts, J. T. M., Goethals, M., Gregoire, J. -M., Haine, E., Herbots, T., Hoffer, E., Hutse, W. H. J., Kassab, A., Lafontaine, P., Lancellotti, P., Lefebvre, P., Lesseliers, H., Lozano, A., Maamar, R., Martinez, C., Noel, J. -F., Odent, G., Pasquet, A., Peperstraete, B., Purnode, P., Rogowsky, A., Rosseel, M., Salembier, J. -P., Surmont, P., Thermol, P., Vandeplas, A. M. F., Van de Walle, S., Vandergoten, P., Vanhauwaert, B. G., Vanneste, L., Vercammen, J., Verleyen, D., Vermander, D., Vervoort, G., Weytjens, C., Yanni, N., da Costa Pereira, A., Rocha de Lorenzo, A., Felice Castro Issa, A., Mahler Mioto, B., de Brito Vianna, C., Segre, C. A. W., Grupi, C. J., Okawabata, C., Favarato, D., Giusti Rossi, E., Fernandes, F., Pitella, F., Alvarez Ramires, F. J., Henpin Yue Cesena, F., Monteiro Ferreira, J. F., Junior, J. F., Tonet, L., Nastari, L., Machado Cesar, L., Gowdak, L. H., Matos, M. A., Moretti, M., Morgado, P. C., Vicente Amato, R., Tadeu Munhoz, R., Coimbra, S. R., Luqman, H. N., Yakovova, S., Mantcheva, M., Mincheva, V., Baurenski, L., Karastanev, K., Yordanova, V., Peneva, Y., Bailey, A., Wong, P., Fagan, M., Sabe-Affaki, G., Villasenor, F. M., Belisle, P., Son, W. K., Manyari, D. E., Giacomantonio, N., Lubelsky, B. J., Ezekiel, D., Leong, J. C. S., Grover, A., Vavougios, J., Pesant, Y., Kushner, A. M., Yeung, M. M. M., Vertes, G. E., Nasser-Sharif, F. J., Abdulla, A. H. K., Spensieri, D., Roy, A., Nguyen, T. T., Leclair, M., Morra, P., Everton Biglow, C., Baril, J. F., Lai, K., Wong, D. S., Martinho, V., Antoniadis, G. A., Searles, G. R., Rouse, D., Brisson, G., King Wong, S., Collette, R. S., M. S. C., Ho, Constance, C., Gendreau, R., Kellam, G. W., Cieza Lara, T. A., Boyrazian, H. A., Shamsuzzaman, M., Spink, D. R., Wong, A. P. T., Grewal, R. S., Che, C., Janes, J., Hechtenthal, N., Czarnecka, M., Saulnier, D., Levesque, G., Clavette, P. F., Kennedy, D. R., Kokis, A., Orenstein-Lyall, T. L., Shekhar Pandey, A., Robb, J., Verret, G., Czarnecki, W., Tsui, W. W. H., Perreault, F., Chouinard, G., Lafrance, G., Fullerton, G. M., Lavoie, J. P., Le Bouthillier, P., Tran, Q. H., Rodriguez Marrero, I., Ramadan, F. B., Talbot, P., Fazil, M. A., Cha, J. Y. -M., Garg, S., Chehayeb, R., Roy, B., Chan, Y. K., Harlos, H. E., Matheson, H. B., Patel, R., Vaz, G. F., Bhatt, J. S., Liu, E., Ashton, T. H., Sullivan, H., Quinn, L. P., Yared, K., Gupta, A., Sullivan, B., Campbell, J., Pallie, S., Kim, H., Vizel, S., Savard, D., Cherry, J. M., Gold, J., Chiu, S., Brouillette, G., Singh, R. R., Varma, S., Belanger, A., Myburgh, J. L., Berlingieri, J., Nisker, W., Boutros, G., Bakbak, A. I., Healley, W., Lasalle, L., Liu, F., Tu, C., Lv, S., Liu, X., Gao, H., Li, H., Zhao, H., Cao, L., Zhao, S., Wang, Y., Wu, D., Gu, F., Pan, G., Liu, P., Wang, X., Jiang, H., Li, J., Wang, J., Zhang, L., Ke, Y., Li, D., Chen, G., Xue, H., Jin, Q., Dong, W., Chen, Y., Fu, Z., Hu, H., Liang, Q., Yang, X., Zhou, Z., Xu, Z., Shao, C., Zhang, H., Pei, H., Song, L., Yu, M., Guan, T., Tang, Y., Wu, Y., Yang, M., Ceng, Q., Chen, X., Lin, L., Peng, Y., Yan, X., Yao, E., Zheng, X., Chen, B., Chen, H., Chen, W., Wang, R., Zheng, Y., Tan, H., Zhou, S., Zhou, Y., Liu, Z., Lu, Q., Lai, L., Pan, J., Wang, L., Fu, Q., Peng, J., Du, N., Lv, Y., Miao, W., Wang, H., Pu, Y., Wang, T., Dong, M., Gong, L., Zhang, J., Chen, Z., Jiang, Q., Ma, F., Xu, W., Dai, M., Wu, J., Yu, X., Chen, C., Huo, Y., Sun, L., Gao, W., Li, Z., Hu, Y., Chen, M., Li, G., Xue, M., Yao, Y., Pan, X., Sang, Z., Zhao, G., Hang, J., Ma, S., Zhang, G., Zhou, G., Li, W., Zhu, B., Yu, B., Zhu, S., Mao, J., Xu, M., Liu, Q., Huang, Q., Xie, Y., Feng, L., Chen, F., Chen, L., Liu, Y., Pei, X., Sun, A., Tian, Z., Wang, W., Yang, H., Yu, A., Zhang, M., Zhang, C., Guan, X., Zhou, X., Li, Y., Xing, Y., Chen, K., Luo, L., Dong, S., Zhang, Y., Ai, F., Xiong, C., Yang, F., Yang, K., Yan, J., Zhu, M., Zhang, A., Shan, G., Chen, J., Guo, J., Wu, S., Li, L., Liu, R., Yang, Y., Gao, X., Du, Z., Liang, L., Zhao, Y., Qian, J., He, L., Xiong, L., Chen, P., Peng, C., Zhu, J., Liu, J., Xie, X., Jiang, F., Li, A., Yang, Q., Cong, H., Guo, Y., Ren, N., Xiao, J., Zhao, R., Jiang, J., Deng, X., Wang, S., Wu, K., Zhang, X., Du, W., Shuang, D., Wei, J., Yuan, C., Li, F., Ou, X., Ou, Y., Yu, G., Zhang, S., Gao, J., Qian, Z., Wu, G., Zheng, S., Xu, D., Xie, J., Ren, W., Yao, X., Cai, B., Lv, J., Dong, J., Deng, Z., Bozkova, J., Carda, J., Dedkova, S., Dufka, A., Fridrich, J., Hodac, T., Jirmar, R., Kadleckova, A., Karlicek, M., Krupicka, J., Kuchar, J., Lavicka, V., Leso, J., Lorenc, Z., Micko, M., Navratil, P., Petrova, I., Povolna, P., Raisova, L., Raska, P., Ravlyk, V., Schlesingerova, S., Smrckova, E., Sternthal, P., Stursova, H., Vymetal, P., Zaoral, L., Wiggers, P., Markenvard, J., Andersen, L. K., Frost, L., Refsgaard, J., Strange, S., Egstrup, K., Sykulski, R., Hildebrant, P., Haghfelt, T., Ege, M., Cattan, S., Adam-Blanpain, M., Adda, M., Aimouch, N., Ardouin, L., Assouline, S., Aumjaud, A., Barjhoux, C., Baroudi, R., Beaurain, C., Bennouna, M. A., Bernard, A., Bernardeau, C., Blanc, E., Blum-Decary, I., Bodur, G., Boesch, C., Bonal, J., Bonhomme, R., Bonnet, J. L., Bories, J., Bourachot, M. L., Brumelot, F., Brunehaut Petaut, M., Brunschwig, C., Buffet, P., Calmettes, P., Centa, I., Chartier, B., Chemin, P., Chometon, F., Cohen, J., Colin, R., Cottin, Y., Crespo, F., Dabboura, A., David, F., Dehayes, P., Dematteo, P., Dibon, O., Dodemant, P., Dormagen, V., Dreyfus, X., Dubois, J. M., Duclos, F., Ducoudre, M., Duprez, O., Durand, P., Durand, E., Egloff, P., Escande, M., Escourrou Berdou, M. C., Esna Ashari, G., Feldmann, I., Ferrieres, J., Foltzer, E., Fontanet, B., Garandeau, M., Garban, T., Geffroy, S., Gillet, T., Godart, S., Gosse, P., Gratia, P., Greiner, O., Gueusquin, A., Guiu, E., Guy, J. M., Haddad, S., Hennebelle, V., Honorat, S., Hourany, A., Hua, G., Jacquier, P., Jean, S., Jeremiasz, R., Kohler, P., Lacroix, A., Leandri, M., Lemiere, Y., Liautard, M., Loheac, P., Louchart, J. C., Magnus, P., Maheu, B., Malaterre, H. R., Manchet, G., Mantoux, J., Manzi, D., Marachli, M., Maroun, M., Meneveau, N., Messas, E., Mougeolle, J. L., Mouhat, T., Muller, J. J., Naisseh, M., Nocon, P., Onger, D., Ouguoujil, A., Ovize, M., Page, E., Pareathumby, K., Pleskof, A., Poinson, P., Pons, G., Pouderou, P., Poujois, J. N., Probst, V., Prunier, F., Prunier, L., Puel, V., Rechtman, D., Rennert, R., Rijavec, B., Riou, Y., Robert, J., Roche, C., Roul, G., Salaun, B., Saleh, B., Sandalian, A., Sander, M., Schenowitz, A., Silvestre, A., Soleille, H., Tabet, S., Tardy, M., Thomas-Richard, F., Truong, B., Varaldi, J., Vial, H., Walch, J. M., Wazana, M., Zeitouni, R., Audibert, H., Alizon, F., Amlaiky, A., Asplanato, M., Baranes, C., Bariaud, M., Bernasconi, F., Bousquet, P., Ceraulo, C., De Geeter, G., Donetti, J., Doucet, B., Doucet, J., Dutoya, T., Ennouchi, D., Fallacher, M. H., Fouquet, G., Fourchard, V., Gdalia, J., Grollier, G., Guerard, S., Jeannerat, P. A., Jobic, Y., Joulie, V., Jourdain, P., Jouve, V., Ketelers, R., Khaznadar, G., Kohan, P., Koujan, B., Lammens, B., Landragin, I., Le Moal, E., M'Bey, D., Maes, F., Maheas Morlet, S., Massabie, R., Meddah, D., Meriaux, F. X., Mestre-Fernandes, C., Meyssonnier, P., Migliore, M., Milewski, J., Millet, J. F., Mingam, S., Nazeyrollas, P., Paganelli, F., Pellerin, F., Petitjean, F., Pinzani, A., Pladys, A., Primot, P., Pucheu, A., Rahali, A., Ravoala, P., Rousson, D., Samama, P., Sardon, M., Silvestri, R., Soskin, P., Tabone, X., Tricot, C., Vaquette, B., Vogel, M., Weingrod, M., Aboyans, V., Amoretti, R., Aubry, J., Berthezene, P., Binet, D., Bonnaud, X., Bonnet, P., Bonny, A., Bouchaya, T., Boureux, C., Bourgeois, J. M., Brottier, L., Cavert, B., Cleron, S., Dechoux, E., Delhomme, C., Detienne, J. P., Dubs, J. P., Faudon, B., Fellous, F., Fressonnet, R., Garaud, Y., Garcia, D., Geneves, M., Gleizes, J. L., Guyetand, C., Hermellin, B., Iovescu, D., Kanner, J. P., Khanoyan, P., Leherissier, A., Maximovitch, A., Merian, B., Messali, P., Moreau, Y., Moyal, J., Payot, L., Petoin Peuch, L., Prevot, J. L., Raymond, P., Relange, D., Reymond, S., Robert, J. F., Rosenstein, H., Schneider, J., Schultz, R., Tanielian, P., Thoin, F., Thomas, L., Touzet, P., Steg, G., Amiel Oster Sauvinet, G., Baylac Domengetroy, F., Chamou, K., Etcheverry, B., Farges, J. L., Fraboulet, J. Y., Goralski, M., Janody, D., Mamez, B., Manlay, W., Paillard, F., Pelier, F., Petit, A., Skonieczny, M., Augarde, R., Fournier, J. B., Liandrat, S., Lim, P., Noury, A. I., Paris, D., Saade, M., Stordeur, J. M., Pornin, M., Galinier, M., Balice-Pasquinelli, M. A., Sosner, P., Yvorra, S., Delcoulx, E., Mouquet, F., Poulard, J. E., Sudre, A., Heno, P., Biausque, F., Guenoun, M., Attia, G., Pouwels, S., Carpentier, L., Verbrugge, E., Ziccarelli, C., Elkohen, M., Tricoire, J., Lang, P., Huttin, O., Altevogt, B. -M., Altmann, U., Baar, M., Berrisch-Rahmel, S., Birkenhagen, A., Blase, I., Blindt, R., Bosch, R., Brattstrom, A., Breuer, H. -H., Castrucci, M., Cicek-Hartvig, S., Cierpka, R., Claus, M., Deissner, M., Drexler, M., Eggeling, T., Eisele, G., Enayat, D., Frickel, S., Gessner, S., Giokoglu, K., Gmehling, J., Goss, F., Grooterhorst, P., Gysan, D. B., Haberl, R., Haerer, W., Hassler jun, N., Heinemann, S., Henschel, F., Hinrichsen, M., Hofer, W., Hofmeister, A., Hoh, G., Horstkotte, E., Jager, F., Jeserich, M., Keil, U., Killat, H., Kimmel, S., Kindel, M., Kindler, P., Kleta, S., Konemann, J., Konig, K., Krause-Allmendinger, H., Kronberg, K., Kruck, I., Mannl, V., Meinel, A., Mentz, G., Meyer-Michael, E., Mibach, F., Moller, S., Muth, S., Nelbock-Huber, E., Ohlmeyer, D., Ozkan-Rashed, Z., Paulus, C. -P., Perings, S., Placke, J., Raters, C., Reifart, N., Rink, A., Rybak, K., Salecker, I., Schermaul, K. -H., Schmidt, E., Schmitz, K. -H., Schon, N., Schroder, T., Sievers, B., Simon, M., Spengler, U., Speth-Nitschke, M., Stumpp, A., Szabo, S., Taggeselle, J., Tamm, A., Thelemann, A., Thelemann, C., Thummel, H., Unger, G., Utech, A., Volmar, J., Wauer, B., Wehr, G., Weinrich, L., Weinrich, R., Windstetter, U., Wirtz, J. H., Wittlich, N., Ziehn, P., Zundorf, P., Al Wahshi, Y., Singh, P. P., Narayan, A., Al Tamimi, F., Al Yazeedi, J., Ayche, M., Al Lawati, A., Al Dhanki, M., Salustri, A., Al Sousi, A., Salah, T., Tamimi, M. Y., Agrawal, A., Wassef, A., Baslaib, F., Al Radaideh, G., Yusufali, A., Bazargani, N., Akbar, M., Abdel Wahab, H., Abdel Malak, S., Ghaly, I., Al Ghool, S., Al Kandari, F., Haiba, M., Alanbaei, M., El Menyar, A., Gomaa, M. M., Khalifa, A., Garadah, T., Avgerinos, C., Gouli, O., Stergiou, D., Alexopoulos, I., Pappas, C., Petropoulos, I., Chatzioakim, G., Pontikakis, N., Priftis, C., Mpompoth, P., Bourazanis, I., Papathanasioy, A., Avlonitis, S., Zakopoulos, C., Koutsimpanis, G., Tsamopoulos, I., Christoforidis, C., Zachos, V., Kalaras, P., Karachaliou, M., Liatas, C., Pournaras, G., Theodorakis, G., Orestis, I., Panisois, K., Chalkiadakis, E., Arfaras, V., Melainis, Kolios, G., Boutsikos, P., Kotsalos, A., Mitropoulos, D., Samothrakitis, A., Svolis, K., Anastasiou, E., Gkinis, T., Dalampyras, P., Kalampalikis, A., Leontaridis, I., Gabriilidis, S., Konstantinidis, I., Plastiras, V., Tarenidis, P., Marozsan, I., Edes, I., Czuriga, I., Cziraki, A., Toth, K., Dongo, A., Turi, P., Forster, T., Borbola, J., Bachmann, B., Masszi, G., Orban, M., Gerges, G., Balogh, G., Bajcsi, E., Sereg, M., Dezsi, C. A., Takacs, I., Nagy, L., Kisjos, B., Janosi, A., Nagy, A., Nagy, K., Buttl, A., Lippai, J., Sziegl, Z., Malkocs, Z., Foldi, A., Fikker, K., Szabo, E., Gupta, R., Natarajan, S., Dalal, J., Saran, R. K., Mehta, A., Samal, M. P., Khan, I. A., Ghose, T., Sawhney, J. P. S., Roy, T., Chandra, S., Modi, S., Singh, M. M., Vijayaraghavan, G., Sreenivasa Murthy, L., Ramesh, S. S., Dayasagar Rao, V., Chenniappan, M. S., Vadavi, A., Kunhali, K., Srinivasa Reddy, K., Thillai Vallal, S., Khera, P., Dasbiswas, A., Ganguly, K., Chatterjee, S. S., Prasad, B., Shukla, D., Trivedi, A. K., Ahuja, R., Deb, J., Rawal, J., Karnik, R., Hiremath, M. S., Kumbla, D. K., Shetty, S. R., Chonkar, N. S., Juneja, L. M., Goyal, B. K., Sheahan, R., Mulvihill, N., Vaughan, C., Fleming, S., Shiels, P., Keelan, P., Kiernan, T., Cosgrave, J., Day, B., Kelly, K., MacNamara, F., Maguire, B., Clifford, A., O'Gara, A., Guardigli, G., Riccioni, G., Pedretti, R., Felis, S., Pernice, V., Lillo, A., Gori, P., Zaca, F., Giacomazzi, F., Terrosu, P., Cernetti, C., Antonicelli, R., Ansalone, G., Balbi, M., Tamburino, C., Tantillo, S., Proietti, F., Mallamaci, V., d'Este, D., Silvestri, F., Magliari, F., Capuano, N., Marchionni, N., Turiel, M., Maxia, P., Marullo, L., Vicentini, A., Pes, G., Caridi, G., Grieco, A., Doronzo, B., Lacche, A., Massari, F., Orazi, S., Antonelli, G., Provvidenza, M., Nicolino, A., Servi, S. D., Sinicropi, G., Maragoni, G., Azzolini, P., Brscic, E., Bongo, A. S., Perna, G., Perna, B., La Rosa, C., Mossuti, E., Ferrante, R., Petrillo, M. E., Castellari, M., Di Pasquale, P., Saporito, F., Alitto, F., Testa, R., Kang, S. M., Koo, B. K., Hong, S. K., Kim, W., Lee, S. H., Seo, H. S., Gwon, H. C., Kang, D. H., Kwon, H. M., Chae, I. H., S. J., Oh, Shin, J. H., Goh, C. W., J. H., Zo, Hong, T. J., Kim, D. S., Cha, T. J., Ryu, J. K., Kim, Y. J., Hwang, J. Y., Hur, S. H., Jeong, M. H., S. K., Oh, Jin, D. K., Jung, K. T., Rhew, J. Y., Lee, S., Jeon, D. W., Kim, S. H., Mintale, I., Latkovskis, G., Hansone, S., Rozkova, N., Baika, A., Jasinkevica, I., Abele, S., Laizane, I., Pontaga, N., Ecina, V., Mihailova, I., Kondratovica, A., Jurgaitiene, R., Slapikas, R., Barauskiene, G., Jankauskiene, E., Reviene, S., Vaisvila, T., Zaronskiene, D., Slapikiene, O. B., Kupstyte, N., Rinkuniene, E., Steponeniene, R., Kojeliene, J., Badariene, J., Dzenkeviciute, V., Sadauskiene, E., Butkuviene, I., Stankevicius, R., Paliulioniene, R., Snikyte, R., Mazutavicius, R., Abdul Rahim, A. A., Mohamed Yusof, A. K., Chee, K. H., Sadiq, A., Ramanaidu, S., Sim, K. H., Ong, T. K., Fong, A. Y. Y., Chang, B. C., Chua, S. K., Cham, Y. L., Moh, d. Amin N. A., Tan, S. K., Chandran, K., Cheah, Y. W., Sinnadurai, J., Choor, C. K., Sia, K. K., Ang, C. C., Singh, J., AbdulWahab, M. Z., Ghapar, A. K., Muthu, A., Kauthaman, M., Jaafar, A. H., K. H., Ng, Tahir, A. R., Abdul Manap, H., Ch'ng, B. S. K., Ch'ng, E. T., Ismail, O., Sahar, A. S., Abdul Kareem, B. B., S. K., Ma, Liew, H. B., Bhaskaran, R. K. M., Shah, R. P., Joseph, K. L., Noor Hasni, H., W. K., Ng, Choo, G. H., Yeo, C. K., Lai, V. M., Lai, Y. C., Tay, M. H., Lim, B. A., Esperon, G. L., de Jeus Zuniga Sedano y America Alvarez, J., Azar Manzur, F., Jerjes Sanchez, C., Cerda Rojas, J., Carrillo Calvillo, J., Petersen Aranguren, F., Martinez Sanchez, C., Vieyra, G., Gonzalez Romero, S., Puente Barragan, A., Redding Escalante, F., Chavez Paez, J., Fernandez Valadez, E., Gaxiola, E., Manautou, L. E., Henne Otero, O., Barrera Bustillos, M., Leyva Pons, J. L., Gomez Alvarez, E., Romo Santana, J. R., Martinez Redding, J., Arias Mendoza, A., Rodriguez Briones, I., de Jeus Rivera Arellano, J., Arenas Leon, J. L., Alcocer Gamba, M., Alexanderson, E., Ruiz Esparza, M. E., Elizondo Sifuentes, L. A., Briseno, J. L., Sandoval, S., Castro, A., Cue Carpio, R., Rodriguez, E., Rojas, G., Solache, G., Diaz, R., Baleon, R., Ferreyra Solorio, C., Alberto Ramirez Reyes, H., Lopez Martinez, M., Romero Maldonado, M. A., Escobedo de la Pena, J., Hilario Jimenez Orozco, J., Reyes Cisneros, F. A., Alvarez Gil, J., Bautista, G., Lopez, Odin de los Rios Ibarra, M., Somsen, G. A., Wittekoek, J. E., Miedema, K., de Sauvage Nolting, P. R. W., Chlewicka, I., Brodzicki, P., Stasiuk, T., Szalkowski, P., Kulig, W., Maliszewski, M., Krolicka, K., Zdrojewska, J., Nikodemska, I., Szpak, A., Wrebiak-Trznadel, M., Prokop, A., Szulc, M., Olszewski, A., Kepa, W., Banach, J., Weglarz, M., Galuszka-Bilinska, A., Krolak, A., Cisowska-Drozd, E., Orzechowski, K., Jezewska, M., Adamaszek, K., Glanowska, G., Pitsch, T., Matuszewska, G., Nowowiejska-Wiewiora, A., Deren, M., Walawski, G., Soltysiak, M., Wysocki, R., Jarosinski, G., Drzewiecka, A., Lugowski, T., Jankowska, A., Blaszczak, P., Drozd, J., Lotocka, E., Duchowska, R., Sobczyk, D., Jarmuzek, P., Sidor, M., Adamczyk-Kot, D., Sudnik, J., Cygler, J., Skoczylas, I., Poprawa, B., Kisiel, L., Kossowska, U., Sikorska-Buczkowska, B., Modzelewska, K., Demianiuk, B., Streb, W., Mularek-Kubzdela, T., Bogdanski, P., Kazmierczak, E., Zimolag, R., Lorenc, J., Furtak, R., Regulska, A., Winter, M., Fic, M., Turek, P., Nowicka, E., Bryl, W., Lenartowska, L., Jerzykowska, O., Mackow, M., Gadzinski, W., Kacorzyk, R., Zalewska, D., Sadlowski, R., Slaboszewska, J., Gruchala, M., Frankiewicz, A., Walczewska, J., Adamkiewicz-Piejko, A., Chyrek, R., Jankowska, L., Correia, A., Girao, A., Herdade, A., Sequeira, A., Tavares E Taveira, A., Gonzaga, A., Ribeiro, A., Albuquerque, A., Fernandes, A., Estriga, A., Rocha De Almeida, A., Lourenco, A., Pereira, A., Faria, A., Carvalho De Moura, B., Camossa, C., Alves, C., Aguiar, C., Rodrigues, C., Wellenkamp, E., Lins, E., Fernandes De Sousa, F., Moreira Pinto, F., Matias, F., Silva Alves, G., Braganca, G., Proenca, G., Pego, G., Vinhas, H., Arroja, I., Rosa Pais, J., Silva E Sa, J., Vasconcelos, J., Matos, J., Freitas, J., Ferreira, J., Costa, J., Alcaravela, J., Mimoso, J., Antunes, J., Ferreira Dos Santos, J., Nobre Dos santos, J., Tito Martins, J., Fernandes, J., Chambel De Aguiar, J., Moreira, J., Carvalho, J., Forte De Carvalho, J., Calaca, J., Simoes, L., Lopes Antunes, L., Soares, L., Semedo, L., Macedo, L., Sargento, L., Basto, L., Carpinteiro, L., Rebelo, L., Oliveira, L., Catarino Carvalho, M., Alves Costa, M., Gamboa, M. C., Ferrao E Vasconcelos, M. F., Custodio, M. H., Mendonca, M. I., Pinto Vaz, M. J., Espiga De Macedo, M., Lazaro, M., Martins Oliveira, M., Pelicano, N., Lousada, N., Rodrigues, O., Matos Dias, P., Fonseca, P. F., Ferreira, P., Abreu, P. E., Monteiro, P., Seabra Gomes, R., Carvalho, R., Santos, R., Pires Pereira, R., Rosado Soares, R., Baptista, S., Reis Monteiro, S., Gil, V., Sanfins, V., Martins, V., Anghel, M., Arsenescu Georgescu, C., Babes, K., Banu, M., Beyer, R., Bratu, I., Bumbu, A., Capalneanu, R., Chioncel, O. D., Chiscaneanu, T., Christodorescu, R., Cindea Nica, N., Cinteza, M., Coman, S., Constantinescu, M., Craiu, E., Dan, G. A., Dan, D. C., Dan, A., David, C. M., Dorobantu, M., Farcas, D., Firastrau, V., Florescu, C., Ghicu, A., Giuca, A., Grigoriu, R., Ionescu, D. A., Ionescu, D. D., Iosipescu, L. C., Ivan, M. V., Lighezan, D., Magheru, S., Magherusan, M., Marinescu, S. M., Motoc, A. C., Musetescu, R., Rau, M., Rotaru, L., Rus, H., Sirbu, O., Sorodoc, L., Spinu, C. M., Stanciulescu, G., Statescu, C., Toringhibel, M., Trambitas, R., Trocan, N., Tudose, A., Vinereanu, D., Zagreanu, M., Dymova, D., Semenova, N., Zherebtsova, A., Fedoskin, V., Gurianova, N., Bolotova, N., Knyazeva, V., Spitsina, T., Sytilina, N., Atamanchuk, N., Giorgadze, M., Zarechnova, S., Kutuzova, S., Sharapova, Y., Stelmakh, I., Sinyukova, O., Rostik, S., Evtukhova, L., Sukhanova, L., Makhieva, T., Tereshko, S., Kolesnikov, V., Kochurov, E., Marchenko, B., Nurgalieva, S., Galeeva, Z., Andreicheva, E., Zakirova, V., Baleeva, L., Minsafina, A., Borodina, N., Arkhipova, Y., Krechunova, T., Scherbak, M., Merkhi, A., Aksyutina, N., Ratovskaya, O., Suglobova, E., Kozhelenko, Y., Potapova, E., Poluyanova, G., Naberezhnova, N., Daniels, E., Atueva, K., Tsaryabina, L., Kurekhyan, A., Khishova, N., Dubinina, E., Demina, O., Mochkina, P., Bukanina, E., Tolpygina, S., Polyanskaya, Y., Malysheva, A., Kheliya, T., Serazhim, A., Voronina, V., Lukina, Y., Dubinskaya, R., Dmitrieva, N., Kuzyakina, M., Khartova, N., Bokuchava, N., Smirnova, E., Esenokova, A., Pavlova, Y., Smirnova, O., Astrakhantseva, P., Bykovskaya, S., Charikova, O., Berdnik, K., Karaseva, T., Zhabina, L., Oleinikova, N., Dzhkha, O., Grigoryan, S., Yakovenko, E., Ivaschenko, T., Kiseleva, I., Shokina, T., Novikova, M., Khodanov, A., Popova, L., Latyntseva, L., Kilaberiya, O., Makarenkova, K., Nosova, N., Gerasimova, T., Boikova, L., Sharapova, N., Kulikova, Y., Pasechnaya, N., Bulakhova, E., Kurochkina, S., Bratishko, I., Likhobabina, O., Panova, E., Voronina, N., Bizyaeva, N., Gusev, O., Nevolina, N., Arsentieva, T., Budanova, I., London, E., Melnikova, Khripun, A., Polyaeva, L., Osadchuk, E., Krasnoslobodskaya, O., Yakimova, N., Lugin, A., Sosnova, Y., Il'ina, E., Kositsina, G., Shanina, I., Kostomarova, S., Malgina, M., Omelchenko, M., Gorlova, I., Eidelman, S., Salakhova, A., Bondarenko, B., Sopia, R., Baboshina, N., Eliseeva, N., Tumarov, F., Petrochenko, N., Khudina, I., Arabadzhi, N., Samakhovets, V., Tkhorzhevskaya, L., Sinotova, T., Zherlitsyna, E., Minkin, S., Petrova, N., Tikhonov, Y., Shmakova, N., Abduvalieva, V., Kuzmicheva, M., Nikolaeva, L., Varezhnikova, O., Dmitrieva, T., Mikhailova, E., Yanina, Y., Kapustina, L., Vazhdaeva, Z., Golovina, G., Fedorova, N., Nikolaeva, I., Fillipova, O., Gareeva, L., Tuktarova, F., Khmelevskikh, N., Karnot, V., Golub, M., Surovtseva, I., Kulygina, V., Shelomova, N., Kruglova, I., Pokrovskaya, I., Rodina, O., Polkina, L., Biryukova, N., Filippova, E., Kotova, E., Ignatieva, T., Alekseeva, T., Gruznykh, L., Mozerova, E., Moksyuta, E., Kosachek, E., Srtumilenko, N., Baranova, O., Voronova, T., Bayakhchan, L., Grudtsina, I., Gorshkova, L., Shamsutdinova, O., Getman, M., Gorodilova, I., Karnaukhova, N., Rotenberger, V., Isaeva, L., Lebischak, G., Ryzhkova, V., Usoltseva, E., Mescharekova, D., Tavlueva, E., Mineeva, E., Stikhurova, M., Kosareva, L., Grechishkina, O., Nikishina, S., Ilyukhina, A., Gureeva, O., Soin, I., Erofeev, S., Lebedev, S., Kudryavtsev, L., Gamzatov, E., Maximchuk, N., Grekhova, L., Kolevatova, L., Kazakovtseva, M., Kolesova, O., Zharikova, L., Kukaleva, V., Starostina, N., Grushetskaya, I., Kazachkova, V., Pashentseva, I., Shimonenko, S., Sirazov, I., Chernozemova, A., Golubeva, O., Mingalaeva, S., Zatsarina, E., Kozlov, D., Davydova, N., Larina, O., Fayez Al-Habib, K., Al-Hersi, A., Al-Baker, H., Al-Faleh, H., Moberik, A., Radwan Arafah, M., Al-Shamiri, M., El-Shaer, F., Al Zaibag, M., Bdeir, M., Suliman, I., Mukhtar, A., Omar, H., Jamiel, A., Elkrail, A., Alanazy, M., Habab, M., Ashmak, K., Nourallah, R., Mak, K. H., Singh, B., Baldev, S., Chee, T. S., Koo, C. C., Low, L. P., Nair, V. P., K. S., Ng, Quek, S. S. S., Tan, E. H. M., A. L. R., Ng, Chuang, H. H., Kaliska, G., Murin, J., Hatalova, K., Gaspar, L., Simkova, I., Dubrava, J., Pjontek, J., Pella, D., Banikova, A., Szentivanyi, M., Kovar, F., Benacka, J., Gonos, I., Fazekas, F., Kycina, P., Poles, J., Pernat, A., Veternik, A., Cernic-Suligoj, N., Kerbev, M., Krajnc, I., Zagozen, P., Alam, A., Brown, B., Luke, B., Variava, E., Nethononda, R., Joubert, S., Matthews, P., Nkombua, L., Antia, V., Bhayat, J., George, S. K., Ranjith, N., Vawda, G. H. M., Govender, S., Soosiwala, I., Shein, K., Panajatovic, M., Flores, J., Khan, M. S. H., Blignaut, S., Coetzee, K., Burgess, L., Freeman, V., Theron, H. D., Arnau Vives, M. A., Abardia Oliva, F. J., Albero Martinez, V., Alegret Colomer, J. M., Alegria Ezquerra, E., Almeida Fernandez, C. A., Alvarenga Recalde, N., Alvarez Aunon, A., Alvarez Garcia, P., Amo Fernandez, C., Amoros Galito, C., Ancin Viguiristi, R., Antona Makoshi, J., Aparici Feal, M., Ardiaca Capell, A., Arnedillo Pardo, J., Arquero Garcia, G., Arrarte Esteban, V., Baquero Alonso, M., Barahona Perez, P., Bardaji Mayor, J. L., Barriales Alvarez, V., Batalla Celorio, A., Bierge Valero, D., Blanco Castineiras, J., Bosa Ojeda, F., Botana Penas, C., Brufau Redondo, H., Bruguera Cortada, J., Cabau Rubies, J., Cabrera Sole, R., Calvo Iglesias, F., Cantabrana Miguel, S., Carrillo Cardoso, R., Casanovas Pie, M., Casas Gimenez, P., Castillo Luena, E., Castillo Moreno, J. A., Castillo Orive, M., Chirivella Gonzalez, A., Chopo Alcubilla, J. M., Climent Paya, V., Cobos Gil, M. A., Colomer Martin, J. L., Concepcion Clemente, A., Cortes Sanchez, R., Cremer Luengo, D., Darnes Soler, S., de Andres Novales, J., De Castro Aritmendiz, R., Delgado Prieto, J. L., Diaz Diaz, J. L., Escobar Cervantes, C., Ezcurdia Sasieta, J., Facila Rubio, L., Falces Salvador, C., Federico Zaragoza, P., Fernandez Alvarez, R., Fernandez de la Cigona, F., Fernandez Lazaro, L. A., Fernandez Leoz, L. C., Fernandez Mouzo, R., Fernandez-Valls Gomez, M., Ferreiro Rodriguez, B., Franco Aranda, C., Freire Corzo, J., Fuertes Alonso, J., Fuertes Beneitez, J., Galve Basilio, E., Garcia Garcia, C., Garcia Gonzalez, M. J., Garcia Ortego, S., Garcia Saavedra, V., Garcia-Moll Marimon, J., Gascuena Rubia, R., Gentille Lorente, D., Gervas Pavon, H., Gilabert Gomez, R., Gomez Barrado, J. J., Gomez Doblas, J. J., Gomez Martinez, M. J., Gonzalez Juanatey, C., Gonzalez Toda, V., Gonzalvez Ortega, M., Gordillo Higuero, E., Hernandez Afonso, J., Herrera Fernandez, D., Homs Espinach, E., Idoate Gastearena, A., Irurita Latasa, M., Izquierdo Gonzalez, R., Jaquet Herter, M., Lagares Carballo, M., Lastra Galan, J. A., Limeres Gonzalez, B., Lopez Aranda, M. A., Lopez Barreiro, L., Lopez Gomez, D., Lopez Granados, A., Lopez Mourino, V., Lopez-Sendon, J. L., Mainar Latorre, L., Marin Araez, E., Marin Ortuno, F., Martin Santana, A., Martinez Florez, J., Martinez Gonzalez, J., Martinez Rivero, J. F., Marzal Martin, D., Mazzanti Mignaqui, G. F., Melero Pita, A., Molina Laborda, E., Montero Gaspar, M. A., Mora Robles, J., Morales Gonzalez, J., Moreno Arribas, J., Moreno Casquete, M. T., Moro Lopez, J. A., Moya Lopez, C., Murga Eizagaechevarria, N., Narro Garcia, F., Navarro Manchon, J., Navas Navas, C., Novo Garcia, E., Nunez Gamero, J. A., Ordonez Espana, A., Ortiz de Murua Lopez, J. A., Orts Soler, E., Otero Chulian, E., Pastor Torres, L., Paule Sanchez, A. J., Paz Bermejo, M. A., Pena Perez, G., Perea Egido, J. A., Perez de Isla, L., Perez Ibiricu, S., Perez Martinez, M. A., Perez Paredes, M., Peris Domingo, E., Pinar Sopena, J., Pindado Rodriguez, C., Pinilla Lozano, M. J., Pinero Ramirez, C., Porras Ramos, Y., Ramos Ariznabarreta, F., Rayo Gutierrez, M., Roca Catalan, J. M., Rodriguez Almodovar, A., Rodriguez Collado, J., Rodriguez Fernandez, A., Rodriguez Fernandez, J. A., Rodriguez Hernandez, J. A., Rodriguez Tejero, I., Romeo Castillejo, I., Romero Alvira, D., Romero Hinojosa, J. A., Romero Menor, C., Rossi Sevillano, P., Rueda Calle, E. C., Rueda Soriano, J., Ruiz Perez, P., Sagastagoitia Gorostiza, T., Sainz Hidalgo, I., Sandin Rollan, M., Santaolalla Rodriguez, S., Santas Olmeda, E., Santos Iglesias, J. L., Sanz Rodriguez, M. L., Segura Laborda, I., Serrano Garcia, S., Sevilla Toral, B., Silva Melchor, L., Simarro Martin-Ambrioso, E., Sola Casado, R., Soriano Navarro, C., Soto Ruiz, M. I., Talavera Calle, P., Torres Diaz, P. L., Troncoso Gil, A., Trujillo Berraquero, F., Ulecia Martinez, M. A., Umaran Sanchez, J., Vaticon Herreros, C., Vazquez Garcia, A., Vega Barbado, J. L., Velasco Espejo-Saavedra, E., Vicente Vera, T., Vida Gutierrez, M., Villar Mariscal, C., Vives Bonato, G., Wu Amen, L., Yanes Bowden, G., Yanez Wonenburger, J. C., Zamorano Gomez, J. L., Zarauza Navarro, J., Monnier, P., Forclaz, A., Grobety, M., Schlueter, L., Vuille, C., Nacht, C. A., Evequoz, D., Ciaroni, S., Domine, F., Berube, J., Hellermann, J., Koller, R., Bourgeois, G., Engel, R., Niederberger, C., Stadler, P., Gnadinger, M., Schmied, C., Wettstein, T., Badorff, C., Hilti, P., Chetelat, C. A., Sepulcri, F., Brunner, H., Schindler, J., Kraus, M., Gmur, W., Bouranasompop, C., Jiraroj-ungkun, W., Lapanun, W., Vivekaphirat, V., Panpunnung, S., Dutsadeevettakul, S., Tasneeyapant, S., Ngamjanyaporn, P., Apitamsuntorn, S., Tantisiriwat, W., Suithichaiyakul, T., Kuanprasert, S., Wongcharoen, W., Phrommintikul, A., Musigchai, C., Chantrarat, T., Uerojanaungkul, P., Apinyasawat, S., Tangcharoen, T., Lertnantakul, M., Wasuwat, A., Harinasuta, J., See, O., Chaithiraphan, V., Boonyasirinant, T., Boonyapisit, W., Kittipovanonth, M., Buakhamsri, A., Piyayotai, D., Hutayanon, P., Junejo, S., Aiyegbayo, O., Ancliff, H., Bradshaw, C., Cervenak, R., Choi, H., George, E., Gilmour, I., Gough, D., Idrissi-Sbai, A., Ingham, J., Al-Khalidi, B., Liston, A., Mackrell, J., Pattison, I., Ramachandran, R., Ray, N., Reddy, G., Sen, I., Shetty, K., Singh, L., Stanley, M., Wallace, A., Weatherhead, M., Gilbert, T., McCansh, G., Higgins, S., Killeen, C., Cromarty, I., Franklin, P., Pinch, E., Dhesi, A., Dernedde, C., Lawrence, M., Simper, H., Noble, M., Dalton, G., Stevens, L., Berry, P., Hand, C., Oliver, R., Jones, H., Sampson, P., Taylor, N., Grogono, R., Dalrymple, J., Martin, A., Thurston, S., Elsby, K., Vallis, M., Morrison, G., Lang, C., Watson, A., Thomson, A., Dougall, H., La Hay, B., Compson, L., McCracken, A., Calder, J., Weber, F., Richmond, D., Brownlie, R., Brown, G., MacCowan, H., Heap, A., Perry, M., Holden, L. A., Scott, G., Haldane, N., Hood, S., Cullen, I., Bell, J., McNaught, P., Sharif, M., Dunn, J., Hay, D., Ross, S., Shaw, R., Hay, L., Langridge, S., Burns, R., Crawford, L., Kennedy, A., Logan, D., McAlavey, P., Brown, M., Costello, P., McLaren, G., Potter, A., McPherson, J., Drijfhout, M., Finlayson, J., Troup, D., Woodall, A., Pearce, J., Williams, S., Parkar, W., Yusuf, A., Benett, I., Bishop, P., Thomas, H., Caldwell, I., Ormiston, P., Kwok, S., Kanumilli, N., Saul, P., Milligan, H., Wilkinson, I., Vance, A., Paul, N., Paul, C., Shaikh, I., Ellis, R., Vites, N., Steeds, R., Goodwin, D., Aftab, A., Banham, S., Chauhan, N., Grocutt, M. S., Gupte, A., Jordan, R., Jheeta, B. S., Ladha, K., Nazir, M., Pal, R., Patel, R. P., McManus, R., Singal, A., Saunders, P., Syed, A. B., Bahal, A., Dau, H., Walker, D. M., McNeilly, R., Bolidai, A., MacCarthy, N., Lawton, D., Vardhani, M., Sengupta, G., Kinloch, D., Howie, F., Serrano-Garcia, A., Paget, S. E., Till, R., Seal, P., Morrell, J., Maxwell, T., Singh, G., Warden, D., Elias, R., Dixon, C., Pandey, R. K., Challenor, V., Davies, S., Gibbs, M., Gillet, A., Goldie, C., Jarvis, I., Johnson, P., Malden, M., Moore, J., Morton, C., Nehrig, K., Sheringham, P., Wilson, G., Halcox, J., O'Connor, I., Ling, K., Edwards, D., Charles, H., Weatherup, A., Davies, E., Watkins, N., Morgan, D., Davies, R., Lindsay, A., Beacock, D., Balai, R., Kirmond, P., Brindle, P., Bundy, C., Cahill, T., Dayani, A., Eavis, P., Mohr, S., Hayne, S., Krasucki, C., Micheals, M., Orpen, I., Parker, I., Sewell, R., Sharp, D., Smith, A., Stevens, A., Upton, J., Victory, J., Wernham, C., Davis, R., Mays, C., Andrews, M., Takhar, J., Travill, C., Choudhury, P., Matta, W., Ihonor, A., O'Dong, C., Rahman, S., Singer, P., Gillam, S., Bath, P. S., Razzaq, N., O'Toole, O., Rowe, P., Williams, H., Allcock, A., Tucker, A., Sprott, V., Kyd, K., Cunliffe, G., Arden, C., Bateman, A., Kassianos, G., Sinclair, D., Turner, C., Jagathesan, R., Sattar, F., Ashford, A., Chukwu, A., Taylor, H., Pradhan, R., Rundell, T., Howlett, R., Bietzk, R., Myint, M., Partington, M., O'Reilly, F., Baverstock, M., Dixon, S., Tennekoon, M., Brand, N., Haimes, P., Keller, P., Whetstone, S., Kovyrshyna, O., Rogozhyna, V., Kiver, T., Vasylenko, V., Kucheryava, L., Salimova, S., Alekseenko, V., Gukov, O., Myhailiv, I., Kardashevskaya, L., Prikolota, O., Bashkirtcev, O., Andreev, E., Tkachenko, L., Mospan, M., Batushkin, V., Safonova, L., Ogorodnichuk, A., Pustovit, S., Romanov, S., Burlakova, L., Voloshko, Y., Lafarenko, V., Vlasuk, Z., Leshchuk, O., Chushak, S., Koval, V., Stasuk, O., Pogrebna, O., Kornienko, S., Tikhonova, S., Fesenko, T., Kuzmina, T., Ushakov, O., Vechtomova, N., Potapska, L., Illushechkin, I., Kryvenkova, E., Lysunets, O., Tsygankov, O., Bardachenko, L., Voloshyna, L., Ginzburg, V., Franskyavichene, L., Korotich, T., Vyshnevaya, N., Bilous, N., Kulinich, S., Kulik, V., Sadykova, I., Berezhna, T., Molotyagina, S., Pham, M. H., Pham, H. T., Khong, N. H., K. B., Do, T. B., Le, P. A., Do, T. C., Do, Nguyen, N. Q., Q. H., Do, K. C., Vu, Pham, N. H., Pham, T. H. T., M. C., Ta, Phan, D. P., Nguyen, T. T. H., Pham, T. T. N., T. L., To, V. T., Le, Dang, L., Bui, L., Pham, T. T. H., Phan, H. H., Bui, T. T. H., Tuong, T. V. A., Nguyen, T. P., Nguyen, T. H., Nguyen, B. K., D. B., Vu, Pham, N. S., T. Q., Do, Pham, T. S., Dang, V. D., D. T., Le, V. C., Do, Nguyen, T. K. L., Luong, H. D., Luu, T. Q., Pham, N. V., Huynh, T. K., N. T. H., Tu, Ngo, K. A., Nguyen, T. T. C., Ong, T. T. L., Doan, V. B., Kim, T. B., T. N., Vo, Tran, T. T. T., Nguyen, T. A., Tran, V. D., Nguyen, A. K., Tran, A. C., Ngo, M. H., N. H., Vu, I. T., Ly, Tran, N. P. H., Tran, L. U. P., Nguyen, T. N., Tran, T. H., Truong, P. H., Mai, T. L., Hoang, V. S., Bui, C. M. A., Dang, V. P., Truong, Q. B., M. P., Vo, Nguyen, V. T., Chau, N. H., T. T. H., Ta, Dinh, H. N., Tran, H., Nguyen, H. K. N., Chung, A., Chung, E., Martina-Hooi, B., Angela, R., Ramoutar, P., Fillet, R., Tilluckdharry, R., Dookie, T., Foster, E., Hart, C., Omardeen, F., Ramphall, S., Lalla, C., Cheng, J., Elliott, V., Falconer, H., Hurlock-Clarke, L., Ishmael, R., Lalljie, G., Lee, K., Liqui-Lung, A., Massay, R., Mohammed, H., Brown, C., Daniel, R., Didier, M., Salas, Z., CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), University of Glasgow, Maria Cecilia Hospital [Cotignola], Royal Brompton Hospital, Montreal Heart Institute Coordinating Centre (MHICC), Université de Montréal (UdeM), Medical University of Silesia (SUM), Université Paris Diderot - Paris 7 (UPD7), Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Dorogoichenko, Aleksandra, Laucevičius, Aleksandras, Jurgaitienė, Rūta, Šlapikas, Rimvydas, Barauskienė, Gražina, Jankauskienė, Edita, Revienė, Sigita, Vaišvila, Tautvydas, Zaronskienė, Danutė, Šlapikienė, Ona Birutė, Kupstytė, Nora, Rinkūnienė, Egidija, Steponėnienė, Rima Vitalija, Kojelienė, Jūratė, Badarienė, Jolita, Dženkevičiūtė, Vilma, Sadauskienė, Eglė, Butkuvienė, Irena, Stankevičius, R., Paliulionienė, R., Snikytė, R., Mažutavičius, R., and CLARIFY Investigators
- Subjects
Male ,Genetics and Molecular Biology (all) ,Heart disease ,medicine.medical_treatment ,atrial fibrillation ,coronary ,anticoagulants ,patients ,atrial flutter ,lcsh:Medicine ,Coronary Artery Disease ,Practice Patterns ,030204 cardiovascular system & hematology ,Chest pain ,Biochemistry ,[SHS]Humanities and Social Sciences ,Cohort Studies ,Coronary artery disease ,Angina ,0302 clinical medicine ,Aged ,Anticoagulants ,Atrial Fibrillation ,Drug Therapy, Combination ,Female ,Guideline Adherence ,Humans ,Outpatients ,Platelet Aggregation Inhibitors ,Practice Patterns, Physicians' ,Registries ,Practice Patterns, Physicians'/statistics & numerical data ,030212 general & internal medicine ,Myocardial infarction ,lcsh:Science ,Stroke ,Anticoagulants/administration & dosage ,Multidisciplinary ,Medicine (all) ,Atrial fibrillation ,Guideline Adherence/statistics & numerical data ,3. Good health ,Combination ,Cardiology ,[SHS] Humanities and Social Sciences ,medicine.symptom ,Research Article ,medicine.medical_specialty ,Coronary Artery Disease/drug therapy ,Agricultural and Biological Sciences (all) ,Biochemistry, Genetics and Molecular Biology (all) ,NO ,03 medical and health sciences ,Drug Therapy ,Internal medicine ,medicine ,Platelet Aggregation Inhibitors/administration & dosage ,Physicians' ,Atrial Fibrillation/drug therapy ,business.industry ,lcsh:R ,Percutaneous coronary intervention ,Outpatients/statistics & numerical data ,medicine.disease ,lcsh:Q ,Human medicine ,business - Abstract
BACKGROUND: Few data are available regarding the use of antithrombotic strategies in coronary artery disease patients with atrial fibrillation (AF) in everyday practice. We sought to describe the prevalence of AF and its antithrombotic management in a contemporary population of patients with stable coronary artery disease.METHODS AND FINDINGS: CLARIFY is an international, prospective, longitudinal registry of outpatients with stable coronary artery disease, defined as prior (≥12 months) myocardial infarction, revascularization procedure, coronary stenosis >50%, or chest pain associated with evidence of myocardial ischemia. Overall, 33,428 patients were screened, of whom 32,954 had data available for analysis at baseline; of these 2,229 (6.7%) had a history of AF. Median (interquartile range) CHA2DS2-VASc score was 4 (3, 5). Oral anticoagulation alone was used in 25.7%, antiplatelet therapy alone in 52.8% (single 41.8%, dual 11.0%), and both in 21.5%. OAC use was independently associated with permanent AF (pCONCLUSIONS: In this contemporary cohort of patients with stable coronary artery disease and AF, most of whom are theoretical candidates for anticoagulation, oral anticoagulants were used in only 47.2%. Half of the patients received antiplatelet therapy alone and one-fifth received both antiplatelets and oral anticoagulants. Efforts are needed to improve adherence to guidelines in these patients.TRIAL REGISTRATION: ISRCTN registry of clinical trials: ISRCTN43070564.
- Published
- 2015
- Full Text
- View/download PDF
18. Determinants of high platelet reactivity in rapid metabolizers with acute coronary syndrome
- Author
-
Collet, J. P., Kerneis, M., Cvetinović, Nataša, Lončar, Goran, Silvain, J., Brugier, D., Barthelemy, O., Vignalou, J. B., Payot, L., Radojičić, Zoran, Mansencal, N., Montalescot, G., Collet, J. P., Kerneis, M., Cvetinović, Nataša, Lončar, Goran, Silvain, J., Brugier, D., Barthelemy, O., Vignalou, J. B., Payot, L., Radojičić, Zoran, Mansencal, N., and Montalescot, G.
- Published
- 2016
19. Extended thromboprophylaxis with betrixaban in acutely ill medical patients
- Author
-
Cohen, A. T., Harrington, R. A., Goldhaber, S. Z., Hull, R. D., Wiens, B. L., Gold, A., Hernandez, A. F., Gibson, C. M., Bello, F., Ferrari, A. E., Jure, H., Macin, S., Oliva, M., Parody, M., Poy, C., Baker, R., Colquhoun, D., Coughlin, P., Finfer, S., Rubinfeld, A., Huber, K., Konig, J., Mathies, R., Pilger, E., Schoenerr, H., Adzerikho, I., Koryk, V., Mikhailova, E., Mitkovskaya, N., Pimanov, S., Polonetsy, L., Soroka, N., Blockmans, D., Delforge, M., Dive, A., Lienart, F., Motte, S., Bizzacchi, J., Fiss, E., Freire, A., Manenti, E., Ramacciotti, E., Raymuno, S., Rocha, A., Saraiva, J. F., Dimov, B., Grigorov, M., Kalpachki, R., Kamenova, Z., Kostadinova, M., Milanova, M., Mincheva, V., Pencheva, G., Raev, D., Runev, N., Stoeva, N., Stoyanov, M., Syulemzova, S., Todorov, G., Tokmakova, M., Dhar, A., Douketis, J., Kahn, S., Le Gal, G., Pearce, M., Provencher, S., Verreault, S., Alarcon, M., Canon, C., Lazcano, M., Cardenas, S., Butkovic-Soldo, S., Car, S., Ciglenecki, N., Francetic, I., Jakopovic, M., Kalinic-Grgorinic, H., Knezevic, A., Malojcic, B., Marusic, S., Vagic, J., Skerk, V., Cermak, O., Chlumsky, J., Chochola, J., Cizek, V., Dunaj, M., Dusek, J., Francek, L., Havelka, J., Herold, M., Holaj, R., Horny, I., Hubac, J., Jajtner, P., Kolman, P., Lang, P., Mayer, O., Mikulova, J., Podpera, I., Reiterer, P., Spacek, R., Vejvoda, J., Vyhnanek, M., Christensen, H., Lassen, M., Storgaard, M., Tuxen, C., Urhammer, S., Lember, M., Marandi, T., Uuetoa, T., Airaksinen, J., Honkaniemi, J., Kaaja, R., Lassila, R., Saarinen, J., Tatlisumak, T., Vikman, S., Agraou, B., Aquilanti, S., Belhassane, A., Brisot, D., De Geeter, G., Debourdeau, P., Decoulx, E., El Kouri, D., Falvo, N., Grange, C., Lacroix, P., Messas, E., Mismetti, P., Montaclair, K., Mottier, D., Paleiron, N., Payot, L., Pernod, G., Pottier, P., Proust, A., Quere, I., Roy, P. M., Schmidt, J., Simoneau, G., Datikashvili-David, I., Khabeishvili, G., Khintibidze, I., Kobulia, B., Megreladze, I., Pagava, Z., Paposhvili, K., Shaburishvili, T., Amann, B., Berrouschot, J., Beyer-Westendorf, J., Blessing, E., Bott, M., Dengler, T., Dziewas, R., Genth-Zotz, S., Hamann, F., Horacek, T., Klimpe, S., Kroning, R., Lapp, H., Lawall, H., Licka, M., Rizos, T., Schellong, S., Tiefenbacher, C., Weimar, C., Zeymer, U., Alkonyi, B., Falukozy, J., Futo, L., Katona, A., Kirschner, R., Kristof, P., Lakatos, F., Laszlo, Z., Lupkovics, G., Merkely, B., Andras, C., Nemeth, L., Papp, A., Soltesz, P., Sudar, Z., Szabo, G., Szegedi, N., Timar, G., Valco, J., Vertes, A., Efrati, S., Elias, M., Gafter, A., Hayek, T., Hussein, O., Lishner, M., Lugassy, G., Zeltser, D., Ageno, W., Cerveri, I., D'Angelo, A., De Pellegrin, A., Imberti, D., Landolfi, Raffaele, Lembo, G., Lodigiani, C., Moia, M., Molteni, M., Mumoli, N., Novo, S., Orlandini, F., Parisi, R., Pizzini, A., Pomero, F., Salvi, A., Schenone, A., Visona, A., Krievins, D., Martinova, V., Pontaga, N., Rozitis, V., Stukena, I., Alekniene, B., Bagdonas, A., Basijokiene, V., Butkiene, Z., Griskeviciene, V., Naudziunas, A., Norvaisiene, R., Norviliene, R., Petrauskiene, R., Poskiene, R., Susinskiene, D., Valavicius, A., Leon, R., Pereyra, R., Karlo, L., Horna, M., Osores, J., Salas, M., Yanez, L., Fryze, W., Gaciong, Z., Gniot, J., Gorecka, D., Gruenpeter, P., Grzelakowski, P., Jastrzebski, D., Kucharski, L., Mirek-Bryniarska, E., Pulkowski, G., Sobkowicz, B., Sulik, P., Tomkowski, W., Walasek, L., Waldemar, K., Wrzesinski, K., Balogh, Z. E., Bojinca, M., Marin, I., Mot, S., Musetescu, R., Podoleanu, C., Popescu, M., Stamate, S., Stanciulescu, G., Vida-Simiti, L., Abashev, A., Andreev, D., Apartsin, K., Arkhipov, M., Averkov, O., Barbarash, O., Belskaya, G., Bogdanov, E., Boldueva, S., Chefranova, Z., Dovgalevskiy, Y., Ershova, O., Goloshchekin, B., Khachatryan, N., Klein, G., Kobalava, Z., Kosmacheva, E., Kostenko, V., Malygin, A., Martynenko, T., Martynenko, V., Maslova, N., Mordovin, V., Nikolaev, K., Nilk, R., Panchenko, E., Popov, D., Privalova, E., Reshetko, O., Sergeeva, E., Shapovalova, Y., Shpagina, L., Shvarts, Y., Simanenkov, V., Solovyov, O., Vishneva, E., Vishnevskiy, A., Apostolovic, S., Celic, V., Ilic, S., Kovacevic-Kuzmanovic, A., Miloradovic, V., Tan, R. S., Bodikova, S., Cervenakova, A., Dvorak, M., Gaspar, L., Herman, O., Hrubon, A., Kokles, M., Krastev, G., Payer, J., Prokop, D., Spisakova, M., Adler, D., Basson, M., Breedt, J., Engelbrecht, J., Jacobson, B., Mitha, I., Van Dyk, C., Sala, L. A., Lopez, C., Bisbe, J., Guardiola, A., Cepeda, J. M., Cereto, F., Santos, E., Ferrer, R., Cerezo, J., Gonzales-Porras, J. R., Grandes, J., Jimenez, D., Mellibovsky, L., Richart, C., Riera, A., Trujillo, J., Nunez, J. A., Villalta, J., Akgul, O., Guneri, S., Kilichesmez, K., Kirma, C., Kutluk, H., Nazliel, B., Okumus, G., Ongen, G., Tigen, K., Topcuoglu, M., Tuncay, E., Abrahamovych, O., Batushkin, V., Brozhyk, J., Burmak, I., Godlevska, O., Goloborodko, A., Goloborodko, B., Goncharova, Y., Gryb, V., Karpenko, O., Kopytsya, M., Koshlia, V., Krakhmalova, O., Kyrychenko, I., Legkonogov, O., Malynovsky, Y., Maslovaskyi, V., Nikonov, V., Parkhomenko, O., Perepeliuk, M., Reshotko, D., Rudenko, L., Ryabichenko, T., Svyridova, I., Svyshchenko, Y., Tseluyko, V., Ursol, G., Vakaliuk, I., Vishnivestsky, I., Voronkov, L., Yagensky, A., Body, R., Davis, M., Maccallum, P., Mccollum, C., Natarajan, I., Almasri, E., Amin, M., Anderson, C., Baker, S., Barney, J., Bastani, A., Bercz, P., Bidair, M., Carman, T., Chang, H., Clark, C., Concha, M., Cornell, J., Dhingra, R., Doshi, A., Farley, B., Fermann, G., Fraiz, J., Fulmer, J., Gaggin, H., Goytia-Leos, D., Hahn, B., Haidar, A., Hamad, A., Hazelrigg, M., Ioachimescu, O., Kabler, H., Kao, C. K., Kazimir, M., Koura, F., Kung, M., Lerner, R., Lopez, J., Macchiavelli, A., Mahal, S., Margolis, B., Mclaren, G., Milling, T., Mittal, M., Nadar, V., Ohaju, V., Ortel, T., Overcash, J., Parthiban, K., Pearl, R., Pineda, L., Pratt, R., Pullman, J., Quintana, O., Rajan, R., Rastogi, P., Rees, C., Rodriguez, W., Saba, F., Shammas, N., Sharma, S., Sokol, S., Stoltz, S., Tuck, M., Updegrove, J., Warner, A., Welch, M., Welker, J., Whitman, B., Wichman, T., Yousef, K., Yusen, R., Zakai, N., Landolfi R. (ORCID:0000-0002-7913-8576), Cohen, A. T., Harrington, R. A., Goldhaber, S. Z., Hull, R. D., Wiens, B. L., Gold, A., Hernandez, A. F., Gibson, C. M., Bello, F., Ferrari, A. E., Jure, H., Macin, S., Oliva, M., Parody, M., Poy, C., Baker, R., Colquhoun, D., Coughlin, P., Finfer, S., Rubinfeld, A., Huber, K., Konig, J., Mathies, R., Pilger, E., Schoenerr, H., Adzerikho, I., Koryk, V., Mikhailova, E., Mitkovskaya, N., Pimanov, S., Polonetsy, L., Soroka, N., Blockmans, D., Delforge, M., Dive, A., Lienart, F., Motte, S., Bizzacchi, J., Fiss, E., Freire, A., Manenti, E., Ramacciotti, E., Raymuno, S., Rocha, A., Saraiva, J. F., Dimov, B., Grigorov, M., Kalpachki, R., Kamenova, Z., Kostadinova, M., Milanova, M., Mincheva, V., Pencheva, G., Raev, D., Runev, N., Stoeva, N., Stoyanov, M., Syulemzova, S., Todorov, G., Tokmakova, M., Dhar, A., Douketis, J., Kahn, S., Le Gal, G., Pearce, M., Provencher, S., Verreault, S., Alarcon, M., Canon, C., Lazcano, M., Cardenas, S., Butkovic-Soldo, S., Car, S., Ciglenecki, N., Francetic, I., Jakopovic, M., Kalinic-Grgorinic, H., Knezevic, A., Malojcic, B., Marusic, S., Vagic, J., Skerk, V., Cermak, O., Chlumsky, J., Chochola, J., Cizek, V., Dunaj, M., Dusek, J., Francek, L., Havelka, J., Herold, M., Holaj, R., Horny, I., Hubac, J., Jajtner, P., Kolman, P., Lang, P., Mayer, O., Mikulova, J., Podpera, I., Reiterer, P., Spacek, R., Vejvoda, J., Vyhnanek, M., Christensen, H., Lassen, M., Storgaard, M., Tuxen, C., Urhammer, S., Lember, M., Marandi, T., Uuetoa, T., Airaksinen, J., Honkaniemi, J., Kaaja, R., Lassila, R., Saarinen, J., Tatlisumak, T., Vikman, S., Agraou, B., Aquilanti, S., Belhassane, A., Brisot, D., De Geeter, G., Debourdeau, P., Decoulx, E., El Kouri, D., Falvo, N., Grange, C., Lacroix, P., Messas, E., Mismetti, P., Montaclair, K., Mottier, D., Paleiron, N., Payot, L., Pernod, G., Pottier, P., Proust, A., Quere, I., Roy, P. M., Schmidt, J., Simoneau, G., Datikashvili-David, I., Khabeishvili, G., Khintibidze, I., Kobulia, B., Megreladze, I., Pagava, Z., Paposhvili, K., Shaburishvili, T., Amann, B., Berrouschot, J., Beyer-Westendorf, J., Blessing, E., Bott, M., Dengler, T., Dziewas, R., Genth-Zotz, S., Hamann, F., Horacek, T., Klimpe, S., Kroning, R., Lapp, H., Lawall, H., Licka, M., Rizos, T., Schellong, S., Tiefenbacher, C., Weimar, C., Zeymer, U., Alkonyi, B., Falukozy, J., Futo, L., Katona, A., Kirschner, R., Kristof, P., Lakatos, F., Laszlo, Z., Lupkovics, G., Merkely, B., Andras, C., Nemeth, L., Papp, A., Soltesz, P., Sudar, Z., Szabo, G., Szegedi, N., Timar, G., Valco, J., Vertes, A., Efrati, S., Elias, M., Gafter, A., Hayek, T., Hussein, O., Lishner, M., Lugassy, G., Zeltser, D., Ageno, W., Cerveri, I., D'Angelo, A., De Pellegrin, A., Imberti, D., Landolfi, Raffaele, Lembo, G., Lodigiani, C., Moia, M., Molteni, M., Mumoli, N., Novo, S., Orlandini, F., Parisi, R., Pizzini, A., Pomero, F., Salvi, A., Schenone, A., Visona, A., Krievins, D., Martinova, V., Pontaga, N., Rozitis, V., Stukena, I., Alekniene, B., Bagdonas, A., Basijokiene, V., Butkiene, Z., Griskeviciene, V., Naudziunas, A., Norvaisiene, R., Norviliene, R., Petrauskiene, R., Poskiene, R., Susinskiene, D., Valavicius, A., Leon, R., Pereyra, R., Karlo, L., Horna, M., Osores, J., Salas, M., Yanez, L., Fryze, W., Gaciong, Z., Gniot, J., Gorecka, D., Gruenpeter, P., Grzelakowski, P., Jastrzebski, D., Kucharski, L., Mirek-Bryniarska, E., Pulkowski, G., Sobkowicz, B., Sulik, P., Tomkowski, W., Walasek, L., Waldemar, K., Wrzesinski, K., Balogh, Z. E., Bojinca, M., Marin, I., Mot, S., Musetescu, R., Podoleanu, C., Popescu, M., Stamate, S., Stanciulescu, G., Vida-Simiti, L., Abashev, A., Andreev, D., Apartsin, K., Arkhipov, M., Averkov, O., Barbarash, O., Belskaya, G., Bogdanov, E., Boldueva, S., Chefranova, Z., Dovgalevskiy, Y., Ershova, O., Goloshchekin, B., Khachatryan, N., Klein, G., Kobalava, Z., Kosmacheva, E., Kostenko, V., Malygin, A., Martynenko, T., Martynenko, V., Maslova, N., Mordovin, V., Nikolaev, K., Nilk, R., Panchenko, E., Popov, D., Privalova, E., Reshetko, O., Sergeeva, E., Shapovalova, Y., Shpagina, L., Shvarts, Y., Simanenkov, V., Solovyov, O., Vishneva, E., Vishnevskiy, A., Apostolovic, S., Celic, V., Ilic, S., Kovacevic-Kuzmanovic, A., Miloradovic, V., Tan, R. S., Bodikova, S., Cervenakova, A., Dvorak, M., Gaspar, L., Herman, O., Hrubon, A., Kokles, M., Krastev, G., Payer, J., Prokop, D., Spisakova, M., Adler, D., Basson, M., Breedt, J., Engelbrecht, J., Jacobson, B., Mitha, I., Van Dyk, C., Sala, L. A., Lopez, C., Bisbe, J., Guardiola, A., Cepeda, J. M., Cereto, F., Santos, E., Ferrer, R., Cerezo, J., Gonzales-Porras, J. R., Grandes, J., Jimenez, D., Mellibovsky, L., Richart, C., Riera, A., Trujillo, J., Nunez, J. A., Villalta, J., Akgul, O., Guneri, S., Kilichesmez, K., Kirma, C., Kutluk, H., Nazliel, B., Okumus, G., Ongen, G., Tigen, K., Topcuoglu, M., Tuncay, E., Abrahamovych, O., Batushkin, V., Brozhyk, J., Burmak, I., Godlevska, O., Goloborodko, A., Goloborodko, B., Goncharova, Y., Gryb, V., Karpenko, O., Kopytsya, M., Koshlia, V., Krakhmalova, O., Kyrychenko, I., Legkonogov, O., Malynovsky, Y., Maslovaskyi, V., Nikonov, V., Parkhomenko, O., Perepeliuk, M., Reshotko, D., Rudenko, L., Ryabichenko, T., Svyridova, I., Svyshchenko, Y., Tseluyko, V., Ursol, G., Vakaliuk, I., Vishnivestsky, I., Voronkov, L., Yagensky, A., Body, R., Davis, M., Maccallum, P., Mccollum, C., Natarajan, I., Almasri, E., Amin, M., Anderson, C., Baker, S., Barney, J., Bastani, A., Bercz, P., Bidair, M., Carman, T., Chang, H., Clark, C., Concha, M., Cornell, J., Dhingra, R., Doshi, A., Farley, B., Fermann, G., Fraiz, J., Fulmer, J., Gaggin, H., Goytia-Leos, D., Hahn, B., Haidar, A., Hamad, A., Hazelrigg, M., Ioachimescu, O., Kabler, H., Kao, C. K., Kazimir, M., Koura, F., Kung, M., Lerner, R., Lopez, J., Macchiavelli, A., Mahal, S., Margolis, B., Mclaren, G., Milling, T., Mittal, M., Nadar, V., Ohaju, V., Ortel, T., Overcash, J., Parthiban, K., Pearl, R., Pineda, L., Pratt, R., Pullman, J., Quintana, O., Rajan, R., Rastogi, P., Rees, C., Rodriguez, W., Saba, F., Shammas, N., Sharma, S., Sokol, S., Stoltz, S., Tuck, M., Updegrove, J., Warner, A., Welch, M., Welker, J., Whitman, B., Wichman, T., Yousef, K., Yusen, R., Zakai, N., and Landolfi R. (ORCID:0000-0002-7913-8576)
- Abstract
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. METHODS: Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days. We performed sequential analyses in three prespecified, progressively inclusive cohorts: patients with an elevated D-dimer level (cohort 1), patients with an elevated D-dimer level or an age of at least 75 years (cohort 2), and all the enrolled patients (overall population cohort). The statistical analysis plan specified that if the between-group difference in any analysis in this sequence was not significant, the other analyses would be considered exploratory. The primary efficacy outcome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism. The principal safety outcome was major bleeding. RESULTS: A total of 7513 patients underwent randomization. In cohort 1, the primary efficacy outcome occurred in 6.9% of patients receiving betrixaban and 8.5% receiving enoxaparin (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 0.65 to 1.00; P = 0.054). The rates were 5.6% and 7.1%, respectively (relative risk, 0.80; 95% CI, 0.66 to 0.98; P = 0.03) in cohort 2 and 5.3% and 7.0% (relative risk, 0.76; 95% CI, 0.63 to 0.92; P = 0.006) in the overall population. (The last two analyses were considered to be exploratory owing to the result in cohort 1.) In the overall population, major bleeding occurred in 0.7% of the betrixaban group and 0.6% of the enoxaparin group (relative risk, 1.19; 95% CI, 0.67 to 2.12; P = 0.55). CONCLUSIONS: Among acutely ill medical patients with an elevated D-dimer level, there was no
- Published
- 2016
20. Évolution des délais et de la prise en charge interventionnelle de l’infarctus du myocarde avec sus décalage du ST à la phase aiguë entre 2007 et 2014
- Author
-
Oueslati, C., primary, Delaunay, R., additional, Zabalawi, A., additional, Payot, L., additional, and Moquet, B., additional
- Published
- 2016
- Full Text
- View/download PDF
21. Mort subite et « Tako-Tsubo inversé » : rechercher une étiologie cérébroméningée !
- Author
-
Boutonnet, M., Villevieille, T., Pelletier, C., Payot, L., Koubbi, A., Gryman, R., Dumas, G., and Bonnevie, L.
- Published
- 2012
- Full Text
- View/download PDF
22. Incidence, diagnostic methods and evolution of left-ventricular thrombus for patients with anterior myocardial infarction and low left-ventricular ejection fraction: A prospective multicenter study
- Author
-
Meurin, P., primary, Brandao Carreira, V., additional, Dumaine, R., additional, Shqueir, A., additional, Milleron, O., additional, Safar, B., additional, Perna, S., additional, Smadja, C., additional, Genest, M., additional, Garot, J., additional, Carette, B., additional, Payot, L., additional, and Tabet, J.Y., additional
- Published
- 2014
- Full Text
- View/download PDF
23. CathLab procedures change induce great improvements in radiation safety for patients and healthcare professionals
- Author
-
Abtan, J., primary, Kerneis, M., additional, Boccara, A., additional, Chaib, A., additional, Payot, L., additional, Sayah, S., additional, Alperin, S., additional, Passefort, S., additional, Koubbi, A., additional, and Gryman, R., additional
- Published
- 2013
- Full Text
- View/download PDF
24. Diagnostic value of cardiac magnetic resonance in patients presenting with chest pain, troponin elevation and unobstructed coronary arteries
- Author
-
Cheriaa, S., primary, Bouziane, A., additional, Passefort, S., additional, Safar, B., additional, Payot, L., additional, Cattan, S., additional, and Milleron, O., additional
- Published
- 2013
- Full Text
- View/download PDF
25. Altered Fibrin Architecture Is Associated With Hypofibrinolysis and Premature Coronary Atherothrombosis
- Author
-
Collet, J.P., primary, Allali, Y., additional, Lesty, C., additional, Tanguy, M.L., additional, Silvain, J., additional, Ankri, A., additional, Blanchet, B., additional, Dumaine, R., additional, Gianetti, J., additional, Payot, L., additional, Weisel, J.W., additional, and Montalescot, G., additional
- Published
- 2006
- Full Text
- View/download PDF
26. Impact of Prior Use or Recent Withdrawal of Oral Antiplatelet Agents on Acute Coronary Syndromes
- Author
-
Collet, J.P., primary, Montalescot, G., additional, Blanchet, B., additional, Tanguy, M.L., additional, Golmard, J.L., additional, Choussat, R., additional, Beygui, F., additional, Payot, L., additional, Vignolles, N., additional, Metzger, J.P., additional, and Thomas, D., additional
- Published
- 2004
- Full Text
- View/download PDF
27. Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin
- Author
-
Montalescot, G., primary, Collet, J.P., additional, Tanguy, M.L., additional, Ankri, A., additional, Payot, L., additional, Dumaine, R., additional, Choussat, R., additional, Beygui, F., additional, Gallois, V., additional, and Thomas, D., additional
- Published
- 2004
- Full Text
- View/download PDF
28. Heart Rate as an Index of Thermal Stress
- Author
-
Meyer, J-P, primary, Martinet, C., additional, and Payot, L., additional
- Published
- 2000
- Full Text
- View/download PDF
29. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial.
- Author
-
Montalescot G, Cayla G, Collet JP, Elhadad S, Beygui F, Le Breton H, Choussat R, Leclercq F, Silvain J, Duclos F, Aout M, Dubois-Randé JL, Barthélémy O, Ducrocq G, Bellemain-Appaix A, Payot L, Steg PG, Henry P, Spaulding C, and Vicaut E
- Abstract
Context: International guidelines recommend an early invasive strategy for patients with high-risk acute coronary syndromes without ST-segment elevation, but the optimal timing of intervention is uncertain.Objective: To determine whether immediate intervention on admission can result in a reduction of myocardial infarction compared with a delayed intervention.Design, Setting, and Patients: The Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention (ABOARD) study, a randomized clinical trial that assigned, from August 2006 through September 2008 at 13 centers in France, 352 patients with acute coronary syndromes without ST-segment elevation and a Thrombolysis in Myocardial Infarction (TIMI) score of 3 or more to receive intervention either immediately or on the next working day (between 8 and 60 hours after enrollment).Main Outcome Measures: The primary end point was the peak troponin value during hospitalization; the key secondary end point was the composite of death, myocardial infarction, or urgent revascularization at 1-month follow-up.Results: Time from randomization to sheath insertion was 70 minutes with immediate intervention vs 21 hours with delayed intervention. The primary end point did not differ between the 2 strategies (median [interquartile range] troponin I value, 2.1 [0.3-7.1] ng/mL vs 1.7 [0.3-7.2] ng/mL in the immediate and delayed intervention groups, respectively; P = .70). The key secondary end point was observed in 13.7% (95% confidence interval, 8.6%-18.8%) of the group assigned to receive immediate intervention and 10.2% (95% confidence interval, 5.7%-14.6%) of the group assigned to receive delayed intervention (P = .31). The other end points, as well as major bleeding, did not differ between the 2 strategies.Conclusion: In patients with acute coronary syndromes without ST-segment elevation, a strategy of immediate intervention compared with a strategy of intervention deferred to the next working day (mean, 21 hours) did not result in a difference in myocardial infarction as defined by peak troponin level.Trial Registration: clinicaltrials.gov Identifier: NCT00442949. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
30. Early vs. late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction. A meta-analysis
- Author
-
Montalescot, G., Borentain, M., Payot, L., Collet, J.P., and Thomas, D.
- Published
- 2004
- Full Text
- View/download PDF
31. Beta-Blocker Interruption or Continuation after Myocardial Infarction.
- Author
-
Silvain J, Cayla G, Ferrari E, Range G, Puymirat E, Delarche N, Guedeney P, Cuisset T, Ivanes F, Lhermusier T, Petroni T, Lemesle G, Bresoles F, Labeque JN, Pommier T, Dillinger JG, Leclercq F, Boccara F, Lim P, Besseyre des Horts T, Fourme T, Jourda F, Furber A, Lattuca B, Redjimi N, Thuaire C, Deharo P, Procopi N, Dumaine R, Slama M, Payot L, El Kasty M, Aacha K, Diallo A, Vicaut E, and Montalescot G
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Drug Administration Schedule, Follow-Up Studies, Hospitalization statistics & numerical data, Kaplan-Meier Estimate, Stroke Volume drug effects, Stroke Volume physiology, Withholding Treatment, Adrenergic beta-Antagonists administration & dosage, Adrenergic beta-Antagonists adverse effects, Myocardial Infarction epidemiology, Myocardial Infarction physiopathology, Myocardial Infarction prevention & control, Myocardial Infarction psychology, Quality of Life, Secondary Prevention methods
- Abstract
Background: The appropriate duration of treatment with beta-blocker drugs after a myocardial infarction is unknown. Data are needed on the safety and efficacy of the interruption of long-term beta-blocker treatment to reduce side effects and improve quality of life in patients with a history of uncomplicated myocardial infarction., Methods: In a multicenter, open label, randomized, noninferiority trial conducted at 49 sites in France, we randomly assigned patients with a history of myocardial infarction, in a 1:1 ratio, to interruption or continuation of beta-blocker treatment. All the patients had a left ventricular ejection fraction of at least 40% while receiving long-term beta-blocker treatment and had no history of a cardiovascular event in the previous 6 months. The primary end point was a composite of death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for cardiovascular reasons at the longest follow-up (minimum, 1 year), according to an analysis of noninferiority (defined as a between-group difference of <3 percentage points for the upper boundary of the two-sided 95% confidence interval). The main secondary end point was the change in quality of life as measured by the European Quality of Life-5 Dimensions questionnaire., Results: A total of 3698 patients underwent randomization: 1846 to the interruption group and 1852 to the continuation group. The median time between the last myocardial infarction and randomization was 2.9 years (interquartile range, 1.2 to 6.4), and the median follow-up was 3.0 years (interquartile range, 2.0 to 4.0). A primary-outcome event occurred in 432 of 1812 patients (23.8%) in the interruption group and in 384 of 1821 patients (21.1%) in the continuation group (risk difference, 2.8 percentage points; 95% confidence interval [CI], <0.1 to 5.5), for a hazard ratio of 1.16 (95% CI, 1.01 to 1.33; P = 0.44 for noninferiority). Beta-blocker interruption did not seem to improve the patients' quality of life., Conclusions: In patients with a history of myocardial infarction, interruption of long-term beta-blocker treatment was not found to be noninferior to a strategy of beta-blocker continuation. (Funded by the French Ministry of Health and ACTION Study Group; ABYSS ClinicalTrials.gov number, NCT03498066; EudraCT number, 2017-003903-23.)., (Copyright © 2024 Massachusetts Medical Society.)
- Published
- 2024
- Full Text
- View/download PDF
32. Ticagrelor vs Clopidogrel for Complex Percutaneous Coronary Intervention in Chronic Coronary Syndrome.
- Author
-
Lattuca B, Mazeau C, Cayla G, Ducrocq G, Guedeney P, Laredo M, Dumaine R, El Kasty M, Kala P, Nejjari M, Hlinomaz O, Morel O, Varenne O, Leclercq F, Payot L, Spaulding C, Beygui F, Rangé G, Motovska Z, Portal JJ, Vicaut E, Collet JP, Montalescot G, and Silvain J
- Subjects
- Humans, Clopidogrel adverse effects, Clopidogrel therapeutic use, Platelet Aggregation Inhibitors adverse effects, Platelet Aggregation Inhibitors therapeutic use, Ticagrelor adverse effects, Ticagrelor therapeutic use, Treatment Outcome, Acute Coronary Syndrome diagnostic imaging, Acute Coronary Syndrome therapy, Acute Coronary Syndrome complications, Myocardial Infarction etiology, Percutaneous Coronary Intervention adverse effects
- Abstract
Background: Whether ticagrelor in chronic coronary syndrome patients undergoing complex percutaneous coronary intervention (PCI) can prevent cardiovascular events is unknown., Objectives: The authors sought to evaluate outcomes of complex PCI and the efficacy of ticagrelor vs clopidogrel in stable patients randomized in the ALPHEUS (Assessment of Loading with the P2Y
12 inhibitor ticagrelor or clopidogrel to Halt ischemic Events in patients Undergoing elective coronary Stenting) trial., Methods: All PCI procedures were blindly reviewed and classified as complex if they had at least 1 of the following criteria: stent length >60 mm, 2-stent bifurcation, left main, bypass graft, chronic total occlusion, use of atherectomy or guiding catheter extensions, multiwire technique, multiple stents. The primary endpoint was a composite of type 4a or b myocardial infarction (MI) and major myocardial injury during the 48 hours after PCI. We compared the event rates according to the presence or not of complex PCI criteria and evaluated the interaction with ticagrelor or clopidogrel., Results: Among the 1,866 patients randomized, 910 PCI (48.3%) were classified as complex PCI. The primary endpoint was more frequent in complex PCI (45.6% vs 26.6%; P < 0.001) driven by higher rates of type 4 MI and angiographic complications (12.2% vs 4.8 %; P < 0.001 and 19.3% vs 8.6%; P < 0.05, respectively). The composite of death, MI, and stroke at 48 hours (12.7% vs 5.1 %; P < 0.05) and at 30 days (13.4% vs 5.3%; P < 0.05) was more frequent in complex PCI. No interaction was found between PCI complexity and the randomized treatment for the primary endpoint (Pinteraction = 0.47) nor the secondary endpoints., Conclusions: In chronic coronary syndrome, patients undergoing a complex PCI have higher rates of periprocedural and cardiovascular events that are not reduced by ticagrelor as compared with clopidogrel., Competing Interests: Funding Support and Author Disclosures The ALPHEUS trial was led by the ACTION Study Group, an academic research organization based at the Pitié-Salpêtrière Hospital (Paris, France). The study was sponsored by Assistance Publique-Hopitaux de Paris and was funded by an unrestricted grant from AstraZeneca. The present work was supported by a grant of the French Federation of Cardiology. Prof Lattuca has received research grants from Biotronik, Boston Scientific, Daiichi Sankyo, Fédération Française de Cardiologie, and the Institute of CardioMetabolism and Nutrition; consulting fees from Daiichi Sankyo and Eli Lilly; and lecture fees from AstraZeneca, Medtronic, and Novartis. Prof Cayla has received consulting fees from Edwards Lifesciences, Medtronic, and Microport CRM; and lecture fees from Amgen, AstraZeneca, Abbott, Bayer, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, Microport, Medtronic, Pfizer, and Sanofi. Prof Ducrocq has received speaker and consulting fees from Abbott, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Novo Nordisk, and Sanofi; has served on steering committees for Amgen, Novo Nordisk, and Janssen; and has been a proctor for Boston Scientific. Dr Laredo has received speaker or consulting fees from Abbott and Biotronik. Dr Kala has received consulting fees from Boston Scientific; and lecture fees from AstraZeneca, Edwards Lifesciences, Novartis, Servier, and Terumo. Prof Varenne has received research grants from Abbott and Boston Scientific; and lecture fees from Abbott, AstraZeneca, Boston Scientific, and Servier. Prof Spaulding has received consulting fees from Edwards Lifesciences, Medtronic, Sonivie, Techwald, and Valcare; has received speaker fees from Amgen and Edwards Lifesciences; and is stock shareholder of Techwald and Valcare. Prof Beygui has received consulting and lecture fees from Medtronic, Novartis, and Pfizer; and research grants from Biosensors and Medtronic. Dr Rangé has received speaker or consulting fees from Abbott and Microport. Prof Vicaut has received consulting or speaker fees from Abbott, Amgen, Bristol Myers Squibb, Celgene, LFB, Pfizer, and Sanofi. Prof Collet has received consulting and lecture fees from AstraZeneca, Boston Scientific, Bristol Myers Squibb, COR2ED, Lead-Up, Medtronic, and WebMD. Prof Montalescot has received research grants and consulting or speaker fees from Abbott, Amgen, AstraZeneca, Ascendia, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Boston Scientific, Celecor, CSL Behring, Idorsia, Lilly, Novartis, Novo, Opalia, Pfizer, Quantum Genomics, Sanofi, and Terumo. Prof Silvain has received research grants and consulting or speaker fees from AstraZeneca, Bayer HealthCare SAS, Abbott Medical, Biotronik, Boehringer Ingelheim France, CSL Behring SA, Gilead Science, and Sanofi France; and is stock Shareholder of Pharmaseeds, Terumo, and Zoll. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
33. Safety and Efficacy of a Hybrid Approach Combining a Paclitaxel-Coated Balloon With a New Generation Drug-Eluting Stent in Patients With De Novo True Coronary Bifurcation Lesions.
- Author
-
Kasbaoui S, Payot L, Zabalawi A, Delaunay R, Amara WB, Boukhris M, and Taldir G
- Subjects
- Humans, Paclitaxel adverse effects, Treatment Outcome, Coronary Angiography methods, Drug-Eluting Stents adverse effects, Angioplasty, Balloon, Coronary adverse effects, Angioplasty, Balloon, Coronary methods, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Coronary Artery Disease complications, Coronary Restenosis etiology
- Abstract
Background: The use of drug-coated balloon in the management of true bifurcation lesions appears to be an attractive option to reduce the rate of stent thrombosis and restenosis particularly at the level of the side branch ostium. We aim to assess the safety and the efficacy of a hybrid approach combining a drug-eluting stent in the main branch and a drug-coated balloon to treat the side branch ostium in patients with de novo true bifurcation., Methods: From September 2020 to March 2022, 45 patients with a de novo true bifurcation lesion Medina (1.1.1) or Medina (0.1.1) were enrolled. All patients underwent a percutaneous coronary intervention with the hybrid approach. Clinical assessment with functional stress imaging test was scheduled at 6 months. In case of documented ischemia, coronary angiography was performed. The primary endpoint was the composite of target lesion failure at 6 months including cardiac death, target vessel MI or ischemia-driven target lesion revascularization. The secondary endpoints were technical success, defined by performing the percutaneous coronary intervention without an additional drug-eluting stent at the level of the side branch ostium, and clinical success, defined by a technical success associated with the absence of severe complications during in-hospital phase., Results: The immediate results show a technical success of the procedure in the majority of cases (88.9 %) with a low rate of bailout side branch stenting (11.1 %). The clinical success was obtained in 86.7 % and only one patient experienced a severe in-hospital complication. A side branch ostial lesion length > 10 mm was the only independent predictor of clinical failure of the procedure (OR 12.49, 95 % CI 1.17-133.6; p = 0.037). At 6 months, the TLF was low and occurred in 1 patient (2.2 %). No cardiac death was observed. No TVMI was observed. Importantly, at 6 months, no side branch thrombosis was observed., Conclusion: The use of a hybrid approach combining a drug-eluting stent in the main branch and a drug-coated balloon in the side branch to treat true bifurcation lesions appears to be safe and efficient with few immediate complications and with satisfactory results at mid-term follow up., Competing Interests: Declaration of competing interest None., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
34. βeta blocker interruption after uncomplicated myocardial infarction: rationale and design of the randomized ABYSS trial.
- Author
-
Silvain J, Cayla G, Ferrari E, Range G, Puymirat E, Delarche N, Collet JP, Dumaine R, Slama M, Payot L, Kasty ME, Aacha K, Vicaut E, and Montalescot G
- Subjects
- Humans, Stroke Volume, Quality of Life, Ventricular Function, Left, Adrenergic beta-Antagonists, Treatment Outcome, Myocardial Infarction complications, Heart Failure drug therapy
- Abstract
Background: The long-term use of β-blocker after myocardial infarction (MI) when global left ventricular ejection fraction (LVEF) is preserved has not been studied in the era of modern myocardial reperfusion and secondary prevention therapies. It is unknown whether β-blockers are useful in stable post-MI patients without reduced LVEF and without heart failure., Methods: The Assessment of β-blocker interruption 1 Year after an uncomplicated myocardial infarction on Safety and Symptomatic cardiac events requiring hospitalization (ABYSS) Trial enrolled in 49 centers in France, 3,700 patients with a prior (>6 months) history of MI and a LVEF >40%, chronically treated with a β-blocker and without any major cardiovascular event (MACE) in the past 6 months. These patients were randomized to interruption or continuation of their β-blocker therapy. The primary objective is to demonstrate the noninferiority of interruption vs continuation of the β-blocker therapy on the primary composite endpoint of all-cause death, stroke, MI, hospitalization for any cardiovascular reason at the end of follow-up (accrual follow-up) with a one-year minimum follow-up for the last randomized patient. Secondary objectives will focus on patient reported outcomes with the evaluation of the quality of life before and after randomization with the EQ5D-5L questionnaire. Enrolment has been completed., Conclusion: The ABYSS trial evaluates the cardiovascular safety of β-blocker interruption in stabilized post-MI patients without heart failure nor reduced LVEF. ABYSS trial is a reappraisal of β-blockers life-long therapy in stable post-MI patients without reduced LVEF., Clinical Trial Registration: NCT03498066 (clinicaltrials.gov)., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
35. Aortic valve repair versus mechanical valve replacement for root aneurysm: the CAVIAAR multicentric study.
- Author
-
Lansac E, Di Centa I, Danial P, Bouchot O, Arnaud-Crozat E, Hacini R, Doguet F, Demaria R, Verhoye JP, Jouan J, Chatel D, Lopez S, Folliguet T, Leprince P, Langanay T, Latremouille C, Fayad G, Fleury JP, Monin JL, Mankoubi L, Noghin M, Berrebi A, Pousset S, Laubriet-Jazayeri A, Lafourcade A, Marcault E, Kindo M, Payot L, Bergoend E, Hoffart CJ, Debauchez M, and Tubach F
- Subjects
- Humans, Middle Aged, Aortic Valve surgery, Prospective Studies, Quality of Life, Treatment Outcome, Reoperation adverse effects, Retrospective Studies, Aortic Valve Insufficiency, Cardiac Valve Annuloplasty adverse effects, Aortic Aneurysm surgery, Heart Valve Prosthesis Implantation adverse effects
- Abstract
Objectives: Despite growing evidence that aortic valve repair improves long-term patient outcomes and quality of life, aortic valves are mostly replaced. We evaluate the effect of aortic valve repair versus replacement in patients with dystrophic aortic root aneurysm up to 4 years., Methods: The multicentric CAVIAAR (Conservation Aortique Valvulaire dans les Insuffisances Aortiques et les Anévrismes de la Racine aortique) prospective cohort study enrolled 261 patients: 130 underwent standardized aortic valve repair (REPAIR) consisting of remodelling root repair with expansible aortic ring annuloplasty, and 131 received mechanical composite valve and graft replacement (REPLACE). Primary outcome was a composite criterion of mortality, reoperation, thromboembolic or major bleeding events, endocarditis or operating site infections, pacemaker implantation and heart failure, analysed with propensity score-weighted Cox model analysis. Secondary outcomes included major adverse valve-related events and components of primary outcome., Results: The mean age was 56.1 years, and valve was bicuspid in 115 patients (44.7%). Up to 4 years, REPAIR did not significantly differ from REPLACE in terms of primary outcome [Hazard Ratio (HR) 0.66 (0.39; 1.12)] but showed significantly less valve-related deaths (HR 0.09 [0.02; 0.34]) and major bleeding events (HR 0.37 [0.16; 0.85]) without an increased risk of valve-related reoperation (HR 2.10 [0.64; 6.96]). When accounting for the occurrence of multiple events in a single patient, the REPAIR group had half the occurrence of major adverse valve-related events (HR 0.51 [0.31; 0.86])., Conclusions: Although the primary outcome did not significantly differ between the REPAIR and REPLACE groups, the trend is in favour of REPAIR by a significant reduction of valve-related deaths and major bleeding events. Long-term follow-up beyond 4 years is needed to confirm these findings., (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
36. Early and late ventricular arrhythmias complicating ST-segment elevation myocardial infarction.
- Author
-
Auffret V, Bourenane H, Sharobeem S, Leurent G, Didier R, Gilard M, Nicol PP, Payot L, Filippi E, Hacot JP, Rouault G, Saouli D, Druelles P, Coudert I, Boulanger B, Cherfaoui T, Treuil J, Bedossa M, Boulmier D, Le Guellec M, Martins RP, and Le Breton H
- Subjects
- Aged, Arrhythmias, Cardiac, Humans, Stroke Volume, Ventricular Function, Left, Myocardial Infarction complications, Myocardial Infarction diagnosis, Myocardial Infarction epidemiology, Percutaneous Coronary Intervention adverse effects, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction epidemiology
- Abstract
Background: Ventricular arrhythmias can be life-threatening complications of ST-segment elevation myocardial infarction (STEMI)., Aims: To describe the incidence, predictors and in-hospital impact of early ventricular arrhythmia (EVA, occurring
- Published
- 2022
- Full Text
- View/download PDF
37. On- Versus Off-Hours Presentation and Mortality of ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention.
- Author
-
Lattuca B, Kerneis M, Saib A, Nguyen LS, Payot L, Barthélemy O, Le Feuvre C, Helft G, Choussat R, Collet JP, Montalescot G, and Silvain J
- Subjects
- Aged, Cause of Death, Female, Hospital Mortality, Hospitals, High-Volume, Humans, Male, Middle Aged, Registries, Risk Factors, ST Elevation Myocardial Infarction diagnosis, ST Elevation Myocardial Infarction mortality, Time Factors, Treatment Outcome, After-Hours Care, Patient Admission, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention mortality, ST Elevation Myocardial Infarction therapy
- Abstract
Objectives: The authors sought to assess the association between admission time with patient's care, procedure characteristics, and clinical outcomes within a contemporary ST-segment elevation myocardial infarction (STEMI) network of patients referred for primary percutaneous coronary intervention (PCI)., Background: The effect of admission time on STEMI patient's outcomes remains controversial when primary PCI is the preferred reperfusion strategy., Methods: Characteristics and clinical outcomes of 2,167 consecutive STEMI patients admitted in a tertiary PCI-capable center were collected. On-hours were defined as admission from Monday through Friday between 8 am and 6 pm and off-hours as admission during night shift, weekend, and nonworking holidays. In-hospital and 1-year all-cause mortality were assessed as well as key time delays., Results: A total of 1,048 patients (48.3%) were admitted during on-hours, and 1,119 patients (51.7%) during off-hours. Characteristics were well-balanced between the 2 groups, including rates of cardiac arrest (7.9% vs. 8.8%; p = 0.55) and cardiogenic shock (12.3% vs. 14.7%; p = 0.16). Median symptom-to-first medical contact time and median first medical contact-to-sheath insertion time did not differ according to on- versus off-hours admission (120 min vs. 126 min; p = 0.25 and 90 min vs. 93 min; p = 0.58, respectively), as well as the rate of radial access for catheterization (85.6% vs. 87.5%; p = 0.27). There was no association between on- versus off-hours groups and in-hospital (8.1% vs. 7.0%; p = 0.49) or 1-year mortality (11.0% vs. 11.1%; p = 0.89), respectively., Conclusions: In a contemporary organized STEMI network, patients admitted in a high-volume tertiary primary PCI center during on-hours or off-hours had similar management and 1-year outcomes., (Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
38. Long-Term Evolution of Premature Coronary Artery Disease.
- Author
-
Collet JP, Zeitouni M, Procopi N, Hulot JS, Silvain J, Kerneis M, Thomas D, Lattuca B, Barthelemy O, Lavie-Badie Y, Esteve JB, Payot L, Brugier D, Lopes I, Diallo A, Vicaut E, and Montalescot G
- Subjects
- Adult, Angina, Stable mortality, Anticoagulants, Coronary Angiography, Coronary Artery Disease mortality, Female, Follow-Up Studies, Humans, Inflammation, Male, Middle Aged, Myocardial Infarction mortality, Prognosis, Proportional Hazards Models, Prospective Studies, Recurrence, Registries, Risk Factors, Smoking, Stroke diagnosis, Stroke mortality, Treatment Outcome, Angina, Stable diagnosis, Coronary Artery Disease diagnosis, Myocardial Infarction diagnosis, Myocardial Revascularization
- Abstract
Background: The long-term evolution of premature coronary artery disease (CAD) is unknown., Objectives: The objective of this study was to describe the evolution of coronary atherosclerosis in young patients and identify the risk factors of poor outcomes., Methods: Participants age ≤45 years with acute or stable obstructive CAD were prospectively enrolled and followed. The primary endpoint was all-cause death, myocardial infarction (MI), refractory angina requiring coronary revascularization, and ischemic stroke., Results: Eight hundred-eighty patients with premature CAD were included. They were age 40.1 ± 5.7 years, mainly men, smokers, with a family history of CAD or hypercholesterolemia. At baseline presentation, 91.2% underwent coronary revascularization, predominantly for acute MI (78.8%). Over a follow-up of 20 years, one-third (n = 264) of patients presented with a total of 399 ischemic events, and 36% had at least a second recurrent event. MI was the most frequent first recurrent event (n = 131 of 264), mostly related to new coronary lesions (17.3% vs. 7.8%; p = 0.01; hazard ratio [HR]:1.45; 95% confidence interval [CI]: 1.09 to 1.93 for new vs. initial culprit lesion). All-cause death (n = 55; 6.3%) occurred at 8.4 years (median time). Ethnic origin (sub-Saharan African vs. Caucasian, adjusted hazard ratio [adjHR]: 1.95; 95% CI: 1.13 to 3.35; p = 0.02), inflammatory disease (adjHR: 1.58; 95% CI: 1.05 to 2.36; p = 0.03), and persistent smoking (adjHR: 2.32; 95% CI: 1.63 to 3.28; p < 0.01) were the strongest correlates of a first recurrent event. When considering all recurrent events, the same factors and Asian ethnicity predicted poor outcome, but persistent smoking had the greatest impact on prognosis., Conclusions: Premature CAD is an aggressive disease despite the currently recommended prevention measures, with high rates of recurrent events and mortality. Ethnicity and concomitant inflammatory disease are associated with poor prognoses, along with insufficient control of risk factors., (Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
39. Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention: An Analysis of the Randomized ATOLL Trial.
- Author
-
Liu Z, Silvain J, Kerneis M, Barthélémy O, Payot L, Choussat R, Sabouret P, Cohen M, Pollack CV Jr, Goldstein P, Zeymer U, Huber K, Vicaut E, Collet JP, and Montalescot G
- Subjects
- Aged, Aged, 80 and over, Enoxaparin administration & dosage, Female, Hemorrhage chemically induced, Heparin adverse effects, Humans, Male, Myocardial Infarction therapy, Treatment Outcome, Anticoagulants therapeutic use, Enoxaparin therapeutic use, Fibrinolytic Agents therapeutic use, Heparin therapeutic use, Percutaneous Coronary Intervention methods
- Abstract
Elderly (≥75 years old) patients with ST-segment elevation myocardial infarction (STEMI) have higher ischemic and bleeding risk compared with those <75 years old. We investigated the efficacy and safety of intravenous (IV) enoxaparin versus IV unfractionated heparin (UFH) in elderly patients undergoing primary percutaneous coronary intervention (PCI) for STEMI. A prespecified analysis of the Acute Myocardial Infarction Treated with Primary Angioplasty and Intravenous Enoxaparin or Unfractionated Heparin to Lower Ischemic and Bleeding Events at Short- and Long-term Follow-up (ATOLL) study was performed examining the 30-day outcomes in the elderly patients. Of the 165 elderly patients in the ATOLL study, 85 patients received IV enoxaparin 0.5 mg/kg and 80 patients received IV UFH. Intravenous enoxaparin did not reduce the primary end point, the main secondary efficacy end point, major bleeding, major or minor bleeding, and all-cause mortality compared with IV UFH. The rate of minor bleeding (5.9% vs 22.8%, P
adjusted = .01) was significantly lower with IV enoxaparin compared with IV UFH. Intravenous enoxaparin appears to be a safe alternative to IV UFH in primary PCI of the elderly patients with STEMI., (© The Author(s) 2016.)- Published
- 2017
- Full Text
- View/download PDF
40. Obscurum Per Obscurius. Which Contrast Agent Should Be Contraindicated for Cardiac Shunt Detection (Agitated Saline Agent vs. Ultrasound Contrast Agent)?: Reply to two Letters.
- Author
-
Loncar G and Payot L
- Subjects
- Humans, Male, Dyspnea diagnostic imaging, Echocardiography adverse effects, Hypoxia diagnostic imaging, Ischemic Attack, Transient etiology
- Published
- 2016
- Full Text
- View/download PDF
41. Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome.
- Author
-
Collet JP, Kerneis M, Hulot JS, O'Connor SA, Silvain J, Mansencal N, Brugier D, Abtan J, Barthélémy O, Vignalou JB, Payot L, Rousseau H, Vicaut E, and Montalescot G
- Subjects
- Acute Coronary Syndrome drug therapy, Acute Coronary Syndrome genetics, Aged, Alleles, Blood Platelets cytology, Clopidogrel, Cytochrome P-450 CYP2C19 genetics, Female, Genetic Testing, Genotype, Humans, Male, Middle Aged, Percutaneous Coronary Intervention, Phenotype, Platelet Activation, Platelet Aggregation Inhibitors administration & dosage, Platelet Aggregation Inhibitors chemistry, Platelet Aggregation Inhibitors therapeutic use, Prasugrel Hydrochloride administration & dosage, Prospective Studies, Receptors, Purinergic P2Y12 genetics, Reproducibility of Results, Ticlopidine administration & dosage, Ticlopidine analogs & derivatives, Acute Coronary Syndrome blood, Platelet Function Tests methods, Point-of-Care Testing
- Abstract
Our aim was to demonstrate that the sequential use of the Verigene® rapid CYP2C19 test for genetic profiling and the VerifyNowTM bedside test for platelet function measurement in ACS patients may optimise P2Y12 inhibition. "Rapid" (CYP2C19*1/*1 or CYP2C19*17 carriers, n=211) and "slow" metabolisers (CYP2C19*2 carriers, n=58) were first put on clopidogrel and prasugrel for ≥ 2 weeks, respectively. Patients with low platelet reactivity (PRU<30) on prasugrel or high platelet reactivity (>208 PRU) on clopidogrel were then switched to clopidogrel and prasugrel, respectively. Our objectives were (i) to demonstrate that the proportion of "rapid" metabolisers on 75 mg of clopidogrel within 30-208 (PRU) of P2Y12 inhibition is non-inferior to "slow" metabolisers on prasugrel 10 mg and (ii) to evaluate the same end-point after switching drugs. The proportion of "rapid" and "slow" metabolisers within 30-208 PRU of P2Y12 inhibition was 71% and 56.9%, respectively, an absolute difference of +14.1% (95% CI, -0.05% to 28.28%) with a non-inferiority margin greater than the predefined margin of -10%. Among patients out of target, all but one "slow" metabolisers displayed low-on prasugrel platelet reactivity while the majority of "rapid" metabolisers (68%) displayed high-on clopidogrel platelet reactivity. After switching, the proportion of patients within 30-208 PRU of P2Y12 inhibition was 83.6% and 79.3% in "rapid" and "slow" metabolisers, respectively (+4.3%, 95% CI -7.3% to 15.9%). In conclusion, this study demonstrates a loose relationship between genotype and platelet function phenotype approaches but that they are complementary to select prasugrel or clopidogrel MD in stented ACS patients.
- Published
- 2016
- Full Text
- View/download PDF
42. Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention.
- Author
-
Loncar G, Barthelemy O, Berman E, Kerneis M, Petroni T, Payot L, Choussat R, Silvain J, Collet JP, Helft G, Montalescot G, and Le Feuvre C
- Subjects
- Acute Coronary Syndrome diagnosis, Acute Coronary Syndrome mortality, Acute Coronary Syndrome therapy, Aged, Cause of Death, Chi-Square Distribution, Coronary Artery Disease diagnosis, Coronary Artery Disease mortality, Coronary Artery Disease therapy, Female, France epidemiology, Humans, Kaplan-Meier Estimate, Logistic Models, Male, Middle Aged, Multivariate Analysis, Myocardial Infarction diagnosis, Myocardial Infarction mortality, Myocardial Infarction therapy, Myocardial Ischemia diagnosis, Odds Ratio, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention instrumentation, Prospective Studies, Registries, Renal Insufficiency diagnosis, Renal Insufficiency therapy, Risk Assessment, Risk Factors, Stents, Time Factors, Treatment Outcome, Myocardial Ischemia mortality, Myocardial Ischemia therapy, Percutaneous Coronary Intervention mortality, Renal Insufficiency mortality
- Abstract
Background: Patients with renal failure (RF) have been systematically excluded from clinical trials; consequently their outcomes have not been well studied in the setting of percutaneous coronary intervention (PCI)., Aims: To compare cardiovascular outcomes after contemporary PCI in patients with versus without RF, according to clinical presentation (ST-segment elevation myocardial infarction [STEMI], acute coronary syndrome [ACS] or stable coronary artery disease [sCAD])., Methods: Consecutive patients undergoing PCI with stent were prospectively included from 2007 to 2012. RF was defined as creatinine clearance<60mL/min. The primary endpoint was all-cause mortality; secondary endpoints were major adverse cardiovascular and cerebrovascular events (MACCE: composite of cardiovascular death, myocardial infarction, stroke and target lesion revascularization [TLR]), TLR and Academic Research Consortium definite/probable stent thrombosis (ST) at 1 year., Results: Among 5337 patients, 23% had PCI for STEMI, 34% for ACS and 43% for sCAD, while 27% had RF. RF patients had a higher unadjusted death rate than those with preserved renal function (nRF) in all PCI indication groups (STEMI, 41% vs. 7.5%; ACS, 19% vs. 6%; sCAD, 10% vs. 3%; P<0.0001 for all). The rate of MACCE was also higher in RF patients whatever the PCI indication (STEMI, 45% vs. 15%; ACS, 23% vs. 14%; sCAD, 14% vs. 9%; P<0.05 for all). Rates of TLR (5.5-7.4%) and ST (<2.5%) were similar (P>0.05 for both). sCAD-RF and STEMI-nRF patients had similar rates of mortality (P=0.209) and MACCE (P=0.658). RF was independently associated with mortality, with a doubled relative risk in STEMI versus ACS and sCAD groups (odds ratio 5.3, 95% confidence interval 3.627-7.821 vs. 2.1, 1.465-3.140 and 2.3, 1.507-3.469, respectively; P<0.0001)., Conclusion: RF is a stronger independent predictor of death after PCI in STEMI than in ACS or sCAD patients. sCAD-RF and STEMI-nRF patients had similar prognoses., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
43. TIA Caused by Contrast Echocardiography in Patient with Platypnea-Orthodeoxia.
- Author
-
Loncar G, Payot L, and Dubois M
- Subjects
- Humans, Ischemic Attack, Transient diagnosis, Ischemic Attack, Transient therapy, Magnetic Resonance Imaging, Male, Middle Aged, Posture, Syndrome, Dyspnea diagnostic imaging, Echocardiography adverse effects, Hypoxia diagnostic imaging, Ischemic Attack, Transient etiology
- Abstract
Platypnea-orthodeoxia syndrome (POS) is a rare clinical disorder characterized by dyspnea caused by the upright position and relieved at recumbent position. Few cases of POS and stroke were reported in literature, and the association between stroke and POS with evidence of patent foramen ovale (PFO) is rare. Stroke may occur in patients with cardiac shunt who undergo contrast echocardiography. We present a patient with POS who experienced transitory ischemic attack (TIA) most likely caused by injection of agitated saline microbubbles during screen for PFO. No case report of TIA/stroke during contrast echocardiography in patients with POS has previously been published., (© 2015, Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
44. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
- Author
-
Kerneis M, Silvain J, Abtan J, Hauguel M, Barthélémy O, Payot L, Brugier D, Galier S, Collet JP, and Montalescot G
- Subjects
- Adenosine administration & dosage, Blood Platelets metabolism, Cell Adhesion Molecules blood, Drug Administration Schedule, Female, Humans, Male, Microfilament Proteins blood, Middle Aged, Myocardial Infarction blood, Myocardial Infarction diagnosis, Phosphoproteins blood, Platelet Aggregation drug effects, Platelet Function Tests, Predictive Value of Tests, Prospective Studies, Receptors, Purinergic P2Y12 blood, Receptors, Purinergic P2Y12 drug effects, Ticagrelor, Time Factors, Treatment Outcome, Vasodilator-Stimulated Phosphoprotein, Adenosine analogs & derivatives, Blood Platelets drug effects, Myocardial Infarction therapy, Percutaneous Coronary Intervention adverse effects, Platelet Aggregation Inhibitors administration & dosage, Prasugrel Hydrochloride administration & dosage, Purinergic P2Y Receptor Antagonists administration & dosage
- Abstract
Background: Recent studies have suggested that ticagrelor 90mg twice daily provides stronger platelet inhibition than prasugrel 10mg once daily in acute coronary syndrome patients undergoing percutaneous coronary intervention., Objectives: To compare the effects of ticagrelor 90 mg twice daily and prasugrel 10mg once daily on platelet reactivity in patients with ST-segment elevation myocardial infarction (STEMI), using: the VerifyNow(®) P2Y12 (VN-P2Y12) assay, expressed in P2Y12 reaction units (PRU); measurement of the vasodilator-stimulated phosphoprotein platelet reactivity index (VASP-PRI; %); and light transmission aggregometry (LTA), expressed as residual platelet aggregation (RPA; %)., Methods: Platelet reactivity was evaluated prospectively using the three assays 30 days after primary PCI in 118 patients with STEMI on a maintenance dose of prasugrel 10mg once daily (n=60) or ticagrelor 90mg twice daily (n=58)., Results: On-treatment platelet reactivity, assessed by the VN-P2Y12 assay, was lower for ticagrelor compared with prasugrel (20.91 ± 4.59 PRU vs. 43.50±6.98 PRU; P=0.008) but was not significantly different when using the more specific VASP-PRI assay (13.05 ± 1.61% vs. 17.44 ± 1.97%; P=0.09) or RPA assessed by LTA (10.49 ± 1.44% vs. 7.20 ± 1.27%; P=0.09)., Conclusions: The difference in platelet reactivity between ticagrelor and prasugrel varies according to the platelet function test in patients with STEMI. The differences observed may be related more to the tests than to the drugs used., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
45. Sex-related differences after contemporary primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
- Author
-
Barthélémy O, Degrell P, Berman E, Kerneis M, Petroni T, Silvain J, Payot L, Choussat R, Collet JP, Helft G, Montalescot G, and Le Feuvre C
- Subjects
- Aged, Aged, 80 and over, Comorbidity, Female, France, Hospital Mortality, Hospitals, High-Volume, Humans, Kaplan-Meier Estimate, Logistic Models, Male, Middle Aged, Multivariate Analysis, Myocardial Infarction diagnosis, Myocardial Infarction mortality, Odds Ratio, Prospective Studies, Recurrence, Risk Factors, Sex Factors, Time Factors, Treatment Outcome, Health Status Disparities, Myocardial Infarction therapy, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention mortality
- Abstract
Background: Whether outcomes differ for women and men after percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) remains controversial., Aim: To compare 1-year outcomes after primary PCI in women and men with STEMI, matched for age and diabetes., Methods: Consecutive women with STEMI of<24 hours' duration referred (August 2007 to January 2011) for primary PCI were compared with men matched for age and diabetes. Rates of all-cause mortality, target vessel revascularization (TVR) and major cardiovascular and cerebrovascular events (MACCE) (death/myocardial infarction/stroke) were assessed at 1 year., Results: Among 775 consecutive patients, 182 (23.5%) women were compared with 182 matched men. Mean age was 69±15 years, 18% had diabetes. Patient characteristics were similar, except for lower creatinine clearance (73±41 vs 82±38 μmol/L; P=0.041), more cardiogenic shock (14.8% vs 6.6%; P=0.017) and less radial PCI (81.3% vs 90.1%; P=0.024) in women. Rates of 1-year death (22.7% vs 18.1%), TVR (8.3% vs 6.0%) and MACCE (24.3% vs 20.9%) were not statistically different in women (P>0.05 for all). After exclusion of patients with shock (10.7%) and out-of-hospital cardiac arrest (6.6%), death rates were even more similar (11.3% vs 11.8%; P=0.10). Female sex was not independently associated with death (odds ratio 1.01, 95% confidence interval 0.55-1.87; P=0.97)., Conclusion: In our consecutive unselected patient population, women had similar 1-year outcomes to men matched for age and diabetes, after contemporary primary PCI for STEMI, despite having a higher risk profile at baseline., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
46. Incidence, diagnostic methods, and evolution of left ventricular thrombus in patients with anterior myocardial infarction and low left ventricular ejection fraction: a prospective multicenter study.
- Author
-
Meurin P, Brandao Carreira V, Dumaine R, Shqueir A, Milleron O, Safar B, Perna S, Smadja C, Genest M, Garot J, Carette B, Payot L, and Tabet JY
- Subjects
- Anterior Wall Myocardial Infarction physiopathology, Female, Follow-Up Studies, France epidemiology, Heart Diseases diagnosis, Heart Diseases etiology, Humans, Incidence, Male, Middle Aged, Prospective Studies, Thrombosis diagnosis, Thrombosis etiology, Anterior Wall Myocardial Infarction complications, Heart Diseases epidemiology, Heart Ventricles, Magnetic Resonance Imaging, Cine methods, Stroke Volume physiology, Thrombosis epidemiology, Ventricular Function, Left physiology
- Abstract
Background and Objectives: We aimed to assess the incidence and evolution of left ventricular (LV) thrombi in a high-risk population of patients with LV systolic dysfunction after anterior myocardial infarction (ant-MI). We also compared the accuracy of transthoracic echocardiography (TTE) and cardiac magnetic resonance imaging with contrast-delayed enhancement (CMR-DE) in detecting LV thrombi., Methods: We prospectively included 100 consecutive patients with LV ejection fraction (LVEF) <45% at the first TTE performed <7 days after ant-MI. A second evaluation with TTE and CMR-DE (by blinded examiners) was performed at 30 days. A third TTE and assessment of clinical status were performed between 6 and 12 months after ant-MI., Results: Patients (males 71%; mean age 59.1 ± 12.1 years; mean LVEF 33.5% ± 6.0%) were included at a median of 5.5 days (interquartile range 25th-75th percentile 4.25-6.0 days) after ant-MI. Thrombi were detected among 26 (26%) patients at a median of 12.0 days after ant-MI (7 patients at 1-7 days after MI; 15 at 8-30 days; and 4 after day 30). Sensitivity and specificity for LV thrombi detection were 94.7% and 98.5%, respectively, for TTE as compared with CMR-DE. Most thrombi (n = 24; 92.3%) disappeared after triple antithrombotic therapy (vitamin K antagonist in addition to dual antiplatelet therapy)., Conclusion: Left ventricular thrombus is a frequent complication after ant-MI with systolic dysfunction. When a search for thrombus is prespecified, the accuracy of TTE is high as compared with CMR-DE. The best antithrombotic strategy is not known., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
47. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
- Author
-
Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, and Montalescot G
- Subjects
- Adult, Angioplasty, Balloon, Coronary, Aryl Hydrocarbon Hydroxylases physiology, Clopidogrel, Cytochrome P-450 CYP2C19, Endpoint Determination, Female, Follow-Up Studies, Genotype, Humans, Male, Myocardial Infarction therapy, Proportional Hazards Models, Risk Factors, Secondary Prevention, Stents, Ticlopidine therapeutic use, Aryl Hydrocarbon Hydroxylases genetics, Myocardial Infarction prevention & control, Platelet Aggregation Inhibitors therapeutic use, Polymorphism, Genetic, Ticlopidine analogs & derivatives
- Abstract
Background: Clopidogrel and low-dose aspirin have become the mainstay oral antiplatelet regimen to prevent recurrent ischaemic events after acute coronary syndromes or stent placement. The frequent genetic functional variant 681 G>A (*2) of cytochrome P450 2C19 (CYP2C19) is an important contributor to the wide variability between individuals of the antiplatelet effect of clopidogrel. We assessed whether the CYP2C19*2 polymorphism affected long-term prognosis of patients who were chronically treated with clopidogrel., Methods: Between April 1, 1996, and April 1, 2008, 259 young patients (aged <45 years) who survived a first myocardial infarction and were exposed to clopidogrel treatment for at least a month, were enrolled in a multicentre registry and underwent CYP2C19*2 determination. The primary endpoint was a composite of death, myocardial infarction, and urgent coronary revascularisation occurring during exposure to clopidogrel. Follow-up was every 6 months. The key secondary endpoint was stent thrombosis proven by angiography., Findings: Median clopidogrel exposure time was 1.07 years (IQR 0.28-3.0). Baseline characteristics were balanced between carriers (heterozygous *1/*2, n=64; homozygous *2/*2, n=9) and non-carriers (n=186) of CYP2C19*2 variant. The primary endpoint occurred more frequently in carriers than in non-carriers (15 vs 11 events; hazard ratio [HR] 3.69 [95% CI 1.69-8.05], p=0.0005), as did stent thrombosis (eight vs four events; HR 6.02 [1.81-20.04], p=0.0009). The detrimental effect of the CYP2C19*2 genetic variant persisted from 6 months after clopidogrel initiation up to the end of follow-up (HR 3.00 [1.27-7.10], p=0.009). After multivariable analysis, the CYP2C19*2 genetic variant was the only independent predictor of cardiovascular events (HR 4.04 [1.81-9.02], p=0.0006)., Interpretation: The CYP2C19*2 genetic variant is a major determinant of prognosis in young patients who are receiving clopidogrel treatment after myocardial infarction.
- Published
- 2009
- Full Text
- View/download PDF
48. Feasibility of outpatient coronary angiography with "ad hoc" angioplasty.
- Author
-
Chaumeil A, Beygui F, Collet JP, Payot L, Choussat R, Drobinski G, Le Feuvre C, Helft G, Thomas D, Komajda M, and Montalescot G
- Subjects
- Aged, Angioplasty, Balloon, Coronary adverse effects, Angioplasty, Balloon, Coronary economics, Coronary Angiography adverse effects, Coronary Angiography economics, Coronary Stenosis diagnosis, Coronary Stenosis economics, Cost-Benefit Analysis economics, Female, Hospitalization economics, Humans, Male, Middle Aged, Outcome and Process Assessment, Health Care, Outpatients, Prospective Studies, Radial Artery, Risk Factors, Treatment Outcome, Ambulatory Care economics, Ambulatory Care methods, Angioplasty, Balloon, Coronary methods, Coronary Angiography methods, Coronary Stenosis therapy
- Abstract
To assess the feasibility and safety of coronary angiography combined, where necessary, with ad hoc angioplasty in an outpatient setting; a prospective, single-center study. The first 172 patients (154 men, 59 +/- 11 years) considered at low risk for complications were enrolled for outpatient-coronary angiography with or without angioplasty via a radial approach. The inclusion criteria were clinical, not based on angiography. After angiography/angioplasty, creatinine and troponin were assayed (outside the hospital) within 24h and patients were telephoned and asked about their clinical condition. Angioplasty was performed in 69 (40%) patients and 130 patients (75.6%) were discharged on the same day. In the angioplasty group, a history of coronary dilatation was more common in patients discharged on the same day (p = 0.05), whereas bifurcation lesions were more frequent in subjects who were kept in hospital (p < 0.0001). No serious complications occurred during the study. Of the 42/172 prolonged hospitalizations, eight were due to minor procedural complications, five due to failure of the radial route and three for indications for bypass surgery; the others were kept in for reasons unrelated to a complication (e.g., the examination was performed late in the day, a particularly complex procedure, etc.). Four (3%) of the 24-hour telephone calls led to a visit, but not hospital admission. Overall, performing angiography and "ad hoc" angioplasty in the course of a single outpatient visit makes it possible to foreshorten the hospital stay and increase patient throughput with a given hospital capacity and, this, without increasing clinical risk. Exactly how these patients are selected remains to be defined and may certainly be improved compared to this initial experiment. An outpatient-coronary angiography and ad hoc angioplasty strategy is a viable option with a low risk for patients selected on the basis of simple clinical criteria. It combines the advantages of increased convenience for the patient and lower costs.
- Published
- 2008
- Full Text
- View/download PDF
49. [Antithrombotics in pre-hospital phase of acute coronary syndromes].
- Author
-
Collet JP, Dumaine R, Ecollan P, Beygui F, Choussat R, Boon G, Payot L, and Montalescot G
- Subjects
- Angina, Unstable mortality, Anticoagulants therapeutic use, Humans, Myocardial Infarction mortality, Platelet Aggregation Inhibitors therapeutic use, Platelet Glycoprotein GPIIb-IIIa Complex antagonists & inhibitors, Angina, Unstable drug therapy, Emergency Medical Services, Myocardial Infarction drug therapy, Thrombolytic Therapy methods
- Abstract
Antithrombotic therapies are the corner stone of acute coronary syndrome management. We have the proof that many of them should be initiated during the prehospital care because their clinical benefit is time-dependent. The hypothesis that anticoagulation therapy is an effective treatment of STEMI, which benefit is time-dependent, is now validated. It is also fair to affirm that GP lIb/IIIa receptor inhibitors are the adjuvant therapy of choice for primary PCI. Indeed, these medications reduce short-term and long-term mortality. This clinical benefit is time dependent. Clopidogrel therapy is probably also a medication of the prehospital phase. It is well established now that the biological efficacy of this pro drug is loading dose dependent. It is also demonstrated that its clinical efficacy depends on the time delay between symptom onset and initiation of the therapy. However, the clinical benefit of prehospital administration remains to be established.
- Published
- 2005
50. [Prevalence of asymptomatic atherothrombotic lesions and risk of vascular events in patients with documented coronary artery disease].
- Author
-
Collet JP, Allali Y, Borentain M, Payot L, Raoux F, Cacoub P, Leys D, Alperovitch A, and Montalescot G
- Subjects
- Coronary Artery Disease physiopathology, Female, Humans, Male, Prevalence, Risk Factors, Coronary Artery Disease epidemiology, Coronary Disease physiopathology
- Abstract
Coronary arteries are the most frequent location of atherosclerosis. Coronary artery disease is the first cause of death related to atherothrombosis. In addition, patients with a prior history of acute coronary syndromes exhibit a 10% annual risk of recurrence. Although there seems to be a close correlation between the extension of CAD and the severity of atherosclerotic lesions in extra coronary arterial beds, the prevalence of these extracoronary asymptomatic lesions depends on their location. Hence, the prevalence of renal artery disease defined as stenosis > or = 50% or of peripheral artery disease defined as an ABI < 0.9 is estimated to be 20% up to 30%, whereas the prevalence of both carotid artery disease defined as stenosis > or = 70% or aortic aneurysm is estimated to be 5%. Conversely, the annual absolute risk of stroke among CAD patients is estimated at 1% while it remains unknown for vascular events related to PAD or aortic lesions. These data suggest that a systematic screening for asymptomatic extracoronary atherosclerotic lesions among CAD patients cannot be justified without a better knowledge of the prevalence of these lesions. In addition, the identification of the predicting factors for the presence and the development of these asymptomatic lesions is warranted. Finally, the potential benefit in terms of therapeutic intervention of such screening needs to be evaluated. These important issues warrant further clinical studies with appropriate design.
- Published
- 2005
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.